

## **Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults**

Michael Weller, Emilie Le Rhun, Martin Van den Bent, Susan M. Chang, Timothy F Cloughesy, Roland Goldbrunner, Yong-Kil Hong, Rakesh Jalali, Michael D Jenkinson, Giuseppe Minniti, Motoo Nagane, Evangelia Razis, Patrick Roth, Roberta Rudà, Ghazaleh Tabatabai, Patrick Y Wen, Susan C Short, Matthias Preusser

Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (MW, ELR, PR), Department of Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland (ELR), The Brain Tumour Center at the Erasmus MC Cancer Institute, Rotterdam, The Netherlands (MVdB), Department of Neurological Surgery, Division of Neuro-Oncology, University of California, San Francisco, CA, USA (SMC), Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA (TFC), Center of Neurosurgery, Department of General Neurosurgery, University of Cologne, Cologne, Germany (RG), Brain Tumor Center, Hallym University Sacred Heart Hospital, Anyang, South Korea (YKH), Neuro Oncology Cancer Management Team, Apollo Proton Cancer Centre, Chennai, India (RJ), Department of Neurosurgery, The Walton Centre NHS Foundation Trust & University of Liverpool, Liverpool, UK (MDJ), Department of Medicine, Surgery and Neurosciences, University of Siena, Policlinico Le Scotte, Siena; IRCCS Neuromed, Pozzilli, IS, Italy (GM), Department of Neurosurgery, Kyorin University Faculty of Medicine, Tokyo, Japan (MN), Third Department of Medical Oncology, Hygeia Hospital, 4 Erithrou Stavrou St, Marousi, 15123 Athens, Greece (ER), Division of Neuro-Oncology, Department of Neuroscience, City of Health and Science and University of Turin, Turin, Italy (RR), Department of Neurology & Neuro-Oncology, Hertie Institute for Clinical

Brain Research, Center for Neurooncology, Comprehensive Cancer Center, German Cancer  
© The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Consortium (DKTK), Partner site Tübingen, University Hospital Tübingen, Eberhard Karls University Tübingen, Germany (GT), Center For Neuro-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA (PYW), Leeds Institute of Medical Research, University of Leeds, Leeds, UK and Department of Clinical Oncology, Leeds Teaching Hospitals NHS Trust, Leeds, UK (SCS), Division of Oncology, Department of Medicine 1, Medical University, Vienna, Austria (MP)

**Corresponding author:**

Michael Weller, Prof. Dr. med.

Chairman

University Hospital Zurich, Department of Neurology

Frauenklinikstrasse 26, 8091 Zurich

Telephone +41 44 255 55 00 |

michael.weller@usz.ch, www.neurologie.usz.ch

**Funding:** This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Conflicts of interest:**

**MW** has received research grants from Philogen and Quercis and honoraria for lectures or advisory board participation or consulting from Bayer, Curevac, Medac, Merck (EMD), Novartis, Novocure, Orbus, Philogen, Roche and Sandoz.

**ELR** has received a grant research from Bristol Meyer Squibb and honoraria for lectures or advisory board from Adastr, Bayer, Janssen, Leo Pharma, Pierre Fabre, and Seattle Genetics.

**MvdB** received honoraria for advisory boards from Genenta, Carthera, Boehringer, Astra Zeneca, Chimerix, and Agios.

**SMC** has received an honorarium from AstraZeneca.

**TFC** is cofounder, major stock holder, consultant and board member of Katmai Pharmaceuticals, member of the board and paid consultant for the 501c3 Global Coalition for Adaptive Research, holds stock in Chimerix and receives milestone payments and possible future royalties, member of the scientific advisory board for Break Through Cancer, member of the scientific advisory board for Cure Brain Cancer Foundation, has provided paid consulting services to Sagimet, Clinical Care Options, Ideology Health, Servier, Jubilant, Immvira, Gan & Lee, BrainStorm, Katmai, Sapience, Inovio, Vigeo Therapeutics, DNATrix, Tyme, SDP, Novartis, Roche, Kintara, Bayer, Merck, Boehringer Ingelheim, VBL, Amgen, Kiyatec, Odonate Therapeutics QED, Medefield, Pascal Biosciences, Bayer, Tocagen, Karyopharm, GW Pharma, Abbvie, VBI, Deciphera, VBL, Agios, Genosce, Celgene, Puma, Lilly, BMS, Cortice, Wellcome Trust, Novocure, Novogen, Boston Biomedical, Sunovion, Human Longevity, Insys, ProNai, Pfizer, Notable labs, Medqia Trizel, Medscape and has contracts with UCLA for the Brain Tumor Program with Oncovir, Merck, Oncocutics, Novartis, Amgen, Abbvie, DNATrix, Beigene, BMS, AstraZeneca, Kazia, Agios, Boston Biomedical, Deciphera, Tocagen, Orbus, AstraZeneca, Karyopharm. The Regents of the University of California (T.F.C. employer) has licensed intellectual property co-invented by TFC to Katmai Pharmaceuticals.

**RG** has received travel grants and honoraria for Advisory Boards from AbbVie.

**YKH** has received honoraria for advisory board from Dawonmedax, holds stock in Fieldcure and receives payments for nonexecutive director.

**RJ** has received honoraria and advisory board participation from Mylan Pharmaceuticals and Cipla Limited

**MDJ** has received honoraria or advisory board participation from Brainlab and Novocure.

**GM** received travel grants and honoraria from Brainlab.

**MN** received personal and institutional research grants from AbbVie, Eisai, MSD, Chugai Pharma, Daiichi-Sankyo, Pfizer, Kyowa Kirin, Nippon Kayaku, Tsumura, Shionogi, Otsuka, Astellas, Teijin Pharma, Bayer, Ono Pharma, Asahi Kasei Pharma, Mitsubishi Tanabe Pharma, Sanei, CSF Behring, Hoya technosurgical, and honoraria for lecture, consultation from AbbVie, Daiichi-Sankyo, RIEMSER, Ono Pharma, Novocure, Chugai Pharma, Sumitomo Dainippon Pharma, Daiichi-Sankyo, Nippon Kayaku, Eisai, Kyowa Kirin, UCB Japan, Ohara Pharma.

**ER** has received travel grants from BMS, Roche, Pfizer and Genesis Pharma.

**PR** has received honoraria for lectures or advisory board participation from Bristol-Myers Squibb, Boehringer Ingelheim, Debiopharm, Merck Sharp and Dohme, Novocure, QED, and Roche and research support from Merck Sharp and Dohme and Novocure.

**RR** has received honoraria for lectures or Advisory Board for UCB, Bayer, Novocure, Genenta, Servier.

**GT** received personal and institutional fees for advisory boards (AbbVie, Bayer, Boehringer Ingelheim), consultation (AbbVie, Bayer), as steering committee member (Bayer, Novocure), as speaker (Medac, Novocure, Novartis) and for research grants from Roche Diagnostics and Medac.

**PYW** has received research support from Astra Zeneca/Medimmune, Beigene, Celgene, Chimerix, Eli Lilly, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Puma, Servier, Vascular Biogenics, and VBI Vaccines and honoraria for consulting from Astra Zeneca, Bayer, Black Diamond, Boehringer Ingelheim, Boston Pharmaceuticals, Celularity, Chimerix, Day One Bio, Genenta, Glaxo Smith Kline, Karyopharm, Merck, Mundipharma, Novartis, Novocure, Nuvation Bio, Prelude Therapeutics, Sapience, Servier, Sagimet, Vascular Biogenics, and VBI Vaccines.

**SCS** received honoraria for lectures, advisory boards or consultation from Bayer, Blue Earth, Tocagen and research grant funding from Apollomics.

**MP** has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastr, Gan & Lee Pharmaceuticals.

**Authorship:**

Design and its implementation: MW, ELR, MP

Acquisition, analysis, or interpretation of data: all authors

Writing of the manuscript, revision, approval of the final version: all authors

Accepted Manuscript

## Abstract

Central nervous system (CNS) tumor patients commonly undergo multimodality treatment in the course of their disease. Adverse effects and complications from these interventions have not been systematically studied, but pose significant challenges in clinical practice and impact function and quality of life, especially in the management of long-term brain tumor survivors. Here the European Association of Neuro-Oncology (EANO) has developed recommendations to prevent, diagnose and manage adverse effects and complications in the adult primary brain CNS tumor (except lymphomas) patient population with a specific focus on surgery, radiotherapy and pharmacotherapy. Specifically, we also provide recommendations for dose adaptations, interruptions and re-exposure for pharmacotherapy that may serve as a reference for the management of standard of care in clinical trials. We also summarize which interventions are unnecessary, inactive or contraindicated. This consensus paper should serve as a reference for the conduct of standard therapy within and outside of clinical trials.

## Keywords

Adverse affects, Interruptions, Dose, Re-exposure, Prevention, Toxicity

## Introduction

The therapeutic repertoire of interventions for patients with primary brain tumors is steadily increasing. New interventions are integrated into current standards of care and interactions between novel and standard treatments are often insufficiently studied. Furthermore, how to diagnose and manage complications from cancer treatment is an evolving field. Toxicity in the context of clinical trials is typically captured using Common Terminology Criteria for Adverse Events (CTCAE) criteria <sup>1</sup>. However, there is a paucity of data and consensus on how to prevent adverse events and manage cancer patients once such complications are noted. Therefore, the Guideline Committee of European Association of Neuro-Oncology (EANO) selected a task force from EANO to develop recommendations for clinical practice. These recommendations are restricted to approved or commonly used treatment approaches for primary brain tumors in adults with the exception of primary CNS lymphoma. Novel systemic treatments for extra-CNS cancers are only covered if they have direct implications for neuro-oncology care. Complications from the brain tumors themselves have been addressed elsewhere <sup>2</sup>. Given the broad significance of the topic, the EANO leadership invited colleagues from the US and the Asia Pacific region to review and help develop this guideline, too. Consensus was achieved by several rounds of review and direct personal discussions in some instances. There was no formal voting process on the recommendations.

## Surgery

### *General*

Complications from neurosurgery are inconsistently reported in the neurosurgical literature <sup>3</sup>, although standardization of reporting of surgical complications can improve the safety and quality of treatment <sup>4</sup>. The Landriel Ibañez Classification was developed in 2011 to standardize reporting and classification of surgical and medical complications in patients

undergoing neurosurgery <sup>5</sup>. Neurosurgical complications are graded from I to IV according to severity (Table S1) and can be readily applied to neurosurgical oncology where they maybe more frequently observed than for other brain surgeries <sup>6</sup>. In a cohort of 362 patients operated for a brain tumor, 27 patients (7.5%) experienced an unplanned rehospitalization within 30 days after surgery, mainly due to neurological, infection and venous thromboembolic complications. Nineteen readmissions could have been prevented <sup>3</sup>. All surgical complications in brain tumor patients have management implications, for example, the start of radiotherapy and chemotherapy will be delayed in patients with glioblastoma who have a bone flap infection requiring surgical removal and several weeks of intravenous antibiotics. Furthermore, the prognosis may be adversely affected – particularly if surgical complications result in a deterioration in performance status and neurological function such that the patient is no longer eligible for oncological treatment or participation in clinical trials. Prevention, prophylaxis and minimization of surgical complications are therefore an essential part of patient care. Standard operating procedures and the center's experience with brain tumor surgery may help to reduce the rate of complications and lead to more favourable early post-surgical outcomes <sup>7,8</sup>. MRI including DWI sequences should be obtained within 48-72 h after surgery not only to assess extent of resection, but also to detect local complications such as perioperative ischemia. Patients should be seen at least once after surgery by the operating surgeon in an interval of 2-4 months.

#### *Venous thromboembolic events*

Venous thromboembolic events are common in brain tumor patients, but not primarily a complication of therapeutic interventions, except of surgery. Their prophylaxis and their management are detailed in another EANO ESMO guideline <sup>2</sup>. Sinus venous thrombosis in the brain is an exception because that might directly relate to neurosurgical interventions.



## *Ischemia*

Cerebrovascular accidents are important complications of neurosurgical interventions. The majority of these ischemic events are asymptomatic. The rate of ischemia varies markedly in the literature and depending on the primary tumor type. In a series of 82 “low grade” glioma, 19 patients (23%) had radiological evidence of ischemia after surgery <sup>9</sup>. In a cohort of 245 patients operated for newly diagnosed glioblastoma, 40 patients (16%) had post-operative ischemia, 119 patients (49%) had no ischemia, and 80 patients (33%) had unspecific diffusion-weighted imaging (DWI) lesions on a MRI performed within 72 after surgery with T1-weighted (T1-w) sequences before and after intravenous administration of contrast, T2-weighted sequences and DWI-sequences with calculated ADC-maps <sup>10</sup>. A higher incidence of new ischemic lesions was noted in patients operated for a recurrent glioma (n=20, 80%) as compared to patients with surgery for newly diagnosed glioma (n=26, 31%), and both new permanent and transient neurological deficits were more frequently noted after surgery for recurrent glioma <sup>11</sup>.

Early cerebrovascular complications arise from direct arterial or venous injury during surgery. Meticulous attention to vascular anatomy, main vessels and perforators, and preservation of venous drainage can reduce the risk, however, in higher grade gliomas blood vessels are more fragile and tortuous, and in meningioma the tumor may completely encase arteries and veins risking vessel injury during resection. Other risk factors include potential co-existing medical diseases, such as atrial fibrillation where anticoagulants are stopped pre-operatively. Treatment of peri- and post-operative ischemia is with neuro-rehabilitation and there is no role for thrombolysis in patients with intra-axial malignant tumors due to the risk of intracranial hemorrhage <sup>12</sup>. A neurovascular work-up may be indicated. The risk of ischemic stroke due to embolic occlusion of the middle cerebral artery in the peri-operative period is very low – however, in the rare circumstance where this occurs, mechanical intraarterial thrombectomy may be considered <sup>13 14</sup>.

Regarding initiation of further therapy, it is important to differentiate intraoperative ischemia from hypercoagulable post-operative stroke or embolic stroke which requires a regular stroke work-up. Moreover, surgical devascularization ischemia should not be an exclusion criterium for clinical trials whereas hypercoagulable or embolic stroke might be.

### *Hemorrhage*

Hemorrhage is often reported on post-operative CT or MRI and affects 1.1-4.4% of brain tumor patients<sup>15</sup>. It often remains asymptomatic. Post-operative hemorrhage after biopsies has been noted in 53 of 186 patients (28%) with glioblastoma (volume > 0.05 cm<sup>3</sup> in 17 cases), in 19 of 76 patients (25%) with astrocytoma and in 7 of 25 patients (28%) with oligodendroglioma<sup>16</sup>. Meticulous intra-operative hemostasis will minimize the risk of post-operative hemorrhage. Various surgical techniques are available including bipolar cautery, irrigation and hemostat agents, for example, oxidized cellulose, gelatin matrix and thrombin. Hemorrhage requiring repeat surgery is more likely to occur in patients with underlying clotting disorders or those with poorly controlled hypertension and those with thrombocytopenia which should be ascertained before surgery<sup>17</sup>. Guidelines on the management of antithrombotic and anticoagulant therapy in patients receiving these treatments prior to surgery for a brain tumor are detailed in Table S2. Perioperative hemorrhage unrelated to a coagulation disorder does not constitute a contraindication for the initiation of further treatment such as radiotherapy and chemotherapy.

### *Peri- and postoperative seizures*

Intra- and postoperative seizures are a common problem during surgery using direct cortical stimulation in eloquently located tumors, particularly during awake surgery without seizure protection by general anesthesia. The incidence of intraoperative seizures in awake surgery

ranges from 3.4 to 7.3 percent <sup>18,19</sup>. The practice of postoperative seizure prophylaxis varies widely among physicians, with marked geographic variation <sup>20</sup>. The SNO/EANO practice guideline does not recommend prescribing antiepileptic drugs as primary prophylaxis in the peri- or postoperative situation, even for awake surgery <sup>21</sup>. There are no reliable data on long term seizures after surgery since the cause of epilepsy might be multifactorial.

### *Wound healing*

Surgical wounds should be healed by two weeks following which patients can start oncological treatments including radiotherapy, chemotherapy, and immunotherapy. Bevacizumab should be stopped at least 4 weeks prior to any planned repeat craniotomy to reduce wound healing problems <sup>22</sup>. Similarly, the first dose of bevacizumab should be delayed for 4 weeks post-operatively even after biopsy only and should only be given once the wound has healed <sup>23</sup>. Patients and caregivers should be informed about wound care and symptoms and signs of impaired wound healing.

### *Infections*

Post-operative infections can be categorized as superficial wound infection, bone flap infection, intra-parenchymal abscess, meningitis and ventriculitis. The overall post-operative infection rate in glioma surgery is 0.5-5% <sup>24,15</sup> and recognized risk factors include diabetes, corticosteroids and smoking. The risk of infection is not increased by the use of 5-aminolevulinic acid, ultrasound, awake surgery, or electrophysiology monitoring in patients operated for brain tumors <sup>25</sup>. Despite anecdotal evidence, post-operative bacterial infection does not confer a survival benefit in glioblastoma <sup>26</sup>.

Bundles of care are often implemented to reduce infection rates, e.g., pre- and post-operative medicated hair wash, use of combined chlorhexidine and betadine skin

preparation and administration of peri-operative antibiotics. Definitive evidence to support their use remains conflicting and surgeon and hospital variation exist in practice <sup>27,28,29</sup>. As a minimum, peri-operative antibiotics, careful skin preparation and meticulous attention to aseptic technique by the surgical team are recommended.

Bone flap infections should be managed with bone flap removal and appropriate intravenous antibiotics according to microbiology culture results. If a ventriculoperitoneal shunt or an intraventricular access device for intrathecal chemotherapy become infected, this should be managed with surgical removal of the hardware and appropriate intravenous antibiotics according to microbiology culture results. Appropriate aseptic technique and experienced teams are recommended for the management of such devices.

### *Hydrocephalus*

Post-operative hydrocephalus affects up to 7% of patients undergoing glioma resection <sup>30</sup> and 2.1% of the patients after posterior fossa surgery <sup>31</sup>. Acute hydrocephalus should be managed with emergency external ventricular drain and CSF analysis to ensure there is not co-existing infection. Once CSF is confirmed as sterile and there is confirmed persistent hydrocephalus clinically and on imaging, patients should undergo insertion of a ventriculoperitoneal shunt. Use of antibiotic-impregnated catheters reduces the risk of shunt infection to ~2% <sup>32</sup>. Valve choice is at the discretion of the surgeon.

### **Main expert recommendations**

- Brain tumor surgery should be performed in specialized centers <sup>7,8</sup>
- Risk factors for infection, ischemia and bleeding should be identified and considered prior to surgery

- DWI sequences should be included in the post-operative MRI obtained within 24-72 h after surgery
- Post-operative infections require vigorous treatment per se to avoid delays of further oncological therapies
- Patients and caregivers should be informed about wound care and symptoms and signs potentially associated with complications
- Radiotherapy and systemic antitumor therapy should not be started unless the patient has recovered from postoperative complications and is in a stable condition
- The indication for neurorehabilitation should be routinely assessed after brain tumor surgery <sup>8</sup>

## Radiotherapy

Radiotherapy for patients with brain tumors should be administered at specialized centers. In most patients with primary brain tumors, the target volume of radiotherapy is the tumor with a safety margin, but in certain situations such as widespread disease or for certain entities such as medulloblastoma, whole brain radiotherapy or craniospinal radiotherapy, respectively, are indicated. Treatment plans should adhere to international and national guidelines as applicable. Current advanced radiotherapy techniques including image guidance, intensity modulated, arc delivered photons and protons improve dose conformality and ensure precise dose delivery to the tumor, while limiting exposure of surrounding normal tissues and organs at risk. Nevertheless, significant acute and late treatment-related neurological toxicity can develop, especially in patients receiving high-dose radiotherapy for large volumes or radiotherapy in combination with some systemic therapies.

### *Acute toxicities*

For patients receiving conventionally fractionated radiotherapy, typically 54-60 Gy in 27-33 fractions prescribed to partial brain for most types of primary brain tumors, acute toxicities defined as those occurring during or within a few weeks, by convention < 90 days from the commencement of radiotherapy include hair loss, skin changes (erythema and desquamation) and fatigue. Some patients also experience headache, nausea, vomiting, and signs of raised intracranial pressure from increased edema, as well as worsening of pre-existing focal neurologic deficits and seizure. These acute radiation adverse are usually transient<sup>33</sup>.

Transient systemic dexamethasone may be needed to control symptoms of raised intracranial pressure but systematic prophylactic steroids should not be used. The minimal dose of steroids guided by the clinical neurological evaluation should be used. Radiation dermatitis is characterized by a variety of skin changes, including edema, erythema and dyspigmentation. Skin necrosis may rarely occur after high doses of irradiation or in individuals with radiosensitivity syndromes. Although no standard criteria for its management exists, washing with only mild soap and water and the use of topical corticosteroids have been recommended for radiation dermatitis<sup>34</sup>. Skin toxicity of RT may increase in patients who receive concurrent systemic treatments but this does not include agents commonly administered to patients with primary brain tumors, except for combined BRAF/MEK inhibition. According to the Consensus Guidelines from the Eastern Cooperative Oncology Group, BRAF inhibitors and/or MEK inhibitors should be stopped  $\geq 3$  days before and until after fractionated RT and  $\geq 1$  day before and after SRS<sup>35</sup>. It remains controversial whether co-exposure to older anticonvulsants such as phenytoin and carbamazepine enhances the risk of allergic reactions in patients undergoing RT<sup>36</sup>, but this question has lost clinical relevance

with the introduction of several novel anticonvulsants that are preferred over the old drugs for multiple reasons<sup>2</sup>.

An increasing number of patients undergoing RT have cardiac implantable electronic devices (CIED), cardiac pacemaker (PM) and implanted cardioverters/defibrillator (ICD). Ionizing radiation, especially thoracic RT (as for craniospinal irradiation), can damage a CIED. Therefore, a collaborative multidisciplinary approach is necessary to provide effective and safe RT for patients with CIED. In general, CIED should never be located in the beam, and the beam energy should be limited to 6-10 MV, with the cumulative scatter radiation dose limited to 2 Gy. After the course of RT, CIEDs evaluation should be performed 1, 3, and 6 months due to the risk of latent damage<sup>37</sup>.

RT may need to be interrupted transiently in case of intercurrent disease, compromise in patients' physical or neurological condition, or significant treatment toxicity. Causes of interruption include increased edema leading to neurological symptoms, severe fatigue or uncontrolled nausea and vomiting, especially during concurrent administration of chemotherapy and RT. Every effort must be made to recognize early reactions and to ensure that they are actively managed (steroids, antiemetics including 5-HT<sub>3</sub> receptor antagonists like ondansetron or granisetron, prochlorperazine and metoclopramide<sup>38</sup> to reduce the risk of treatment delay. Bevacizumab (see below) can mitigate RT-associated neurotoxicity and enable treatment to be completed as planned.

Further risks for treatment interruption during RT include the development of neutropenia or thrombocytopenia (or both), especially in the presence of concurrent administration of chemotherapy and increasing volumes of active bone marrow in the radiation field, for example in spinal fields. The need for and frequency of blood value monitoring during RT depends on concurrent treatment, notably cancer chemotherapy, and comorbidities. Grade 3 or 4 hematological toxicity is rarely recorded during RT for small brain volumes, although it occurs in up to 10% of adult patients during craniospinal irradiation (CSI). A transient

interruption of treatment of 3-5 days, reduction of radiation total dose or daily fraction size, and interruption of chemotherapy should be considered in patients with grade 3 or 4 hematological toxicity or febrile neutropenia. It should be noted that for patients receiving RT and concomitant chemotherapy the use of hematopoietic growth factors should be avoided because of the increased risk of complications and death <sup>39,40</sup>.

In patients with fast-growing tumors, such as glioblastoma and medulloblastoma, transient treatment interruption should be compensated increasing the total dose and/or dose per fraction using radiobiological-based calculations <sup>41</sup>.

The management of longer interruptions requires medical decisions to be taken on a case-by-case basis. For patients with rapid worsening of neurological condition due to cancer progression causing severe functional disability or unacceptable treatment toxicity, a premature discontinuation of the treatment should be considered.

#### *Late, commonly irreversible toxicities*

These toxicities occur several months and by definition more than 90 days after treatment and include radionecrosis, cognitive impairment as well as permanent hair loss, hypopituitarism and cataracts <sup>33,42</sup>. Pseudoprogression is commonly defined as an increase of lesion volume of 25% or more that resolves without institution of a new anti-cancer treatment except steroids in the absence of a new lesion whereas radionecrosis is defined as the appearance of necrosis within the treated target volume irrespective of size. Depending on the volume and site, these events can be either asymptomatic or symptomatic. In the AVAglio study, pseudoprogression was observed in 43 of 463 patients (9.3%) treated with standard of care versus 10 of 458 patients (2.2%) of patients treated with bevacizumab in addition to standard of care <sup>43</sup>. The initial observation of an association between pseudoprogression and *MGMT* promoter methylation <sup>44</sup> was not confirmed in the AVAglio study <sup>45</sup>. Radionecrosis is a rare



complication of brain radiotherapy which can develop months to years after radiotherapy. On MRI it appears as increased T2 signal with T1 enhancement, often described as 'soap bubble' in character. Overall, severe toxicity (CTCAE grade 3 or more) is seen in less than 3% of patients when using doses of 50-60 Gy given in 1.8-2.0 Gy per fraction<sup>46</sup>. In contrast, in the setting of reirradiation, the risk of symptomatic radionecrosis ranges from 5-20% depending on dose and irradiated volumes<sup>46,47</sup>. Hypofractionated radiation schedules with total doses of 24-40 Gy given in 3-15 fractions may reduce the risk of brain necrosis associated with single-fraction SRS when treating large (> 3 cm) brain lesions or in the setting of reirradiation<sup>47</sup>.

Symptomatic patients with radionecrosis are usually treated with steroids or the VEGF inhibitor bevacizumab<sup>48,49</sup>, whereas surgery is indicated if suspicion of tumor progression remains or if symptomatic relief of mass effect is desirable.

Neurocognitive changes are well described potential late effects of brain irradiation which occur months to years after treatment in up to 50–90% of adult brain tumor patients who survive more than 6 months post-irradiation, depending on radiation dose and fractionation and treated volumes<sup>50</sup>. The incidence and magnitude may be higher in young adults and several strategies are employed to minimize this complication including avoidance or delay of RT in low grade tumors, reducing the dose in molecularly favourable tumors and employing high-precision RT techniques<sup>51</sup>. The majority of patients treated with whole brain radiotherapy (WBRT) develop deterioration in cognitive function and quality of life<sup>52</sup>, although the incidence can be also significant in the long-term follow up of patients receiving partial brain RT for a brain tumor<sup>53,54</sup>. Limitation of radiation dose to the bilateral hippocampal dentate gyri (hippocampal avoidance) during WBRT may ameliorate neurocognitive decline<sup>55,56</sup>. In young adults with lower grade gliomas and craniopharyngiomas treated to a dose of 54 Gy in 30 fractions at 1.8 Gy per fraction, a mean dose < 30 Gy to left hippocampus as dose constraint prevent neurocognitive decline<sup>57</sup>.

Modern conformal RT techniques, both photon intensity-modulated RT and protons (intensity

modulated proton therapy), should be considered to achieve these constraints in young adults with low grade or benign tumors with expected long-term survival <sup>58,57</sup>.

Proton radiotherapy may also reduce late toxicity by limiting dose to normal brain, although it has not been shown to delay time to cognitive failure in glioblastoma <sup>59</sup>. There is also growing interest in proton therapy for minimizing the incidence of RT-induced lymphopenia which may potentially impact outcome <sup>60,61</sup>.

Memantine intake during WBRT or craniospinal therapy is not recommended considering the absence of convincing data for a protective effect in patients with brain metastases <sup>62</sup>.

Hypopituitarism is a common, dose-dependent late effect when the pituitary dose exceeds 30 Gy and individual hormone deficiencies occur at lower doses, so early identification of deficits to permit replacement therapy is important <sup>29</sup>. Follow up should therefore include regular neurological and endocrinological follow-up and access to appropriate rehabilitation <sup>63</sup>.

Patients with good prognosis tumors should also be made aware of rarer long-term late effects including increased risk of vascular damage and stroke, especially in patients with tumors close to the central arterial circulation <sup>64</sup>. A rare but important complication to recognize and differentiate from recurrence and stroke is the usually self-limiting stroke-like migraine syndrome (SMART) <sup>65</sup>. There is also a low (around 2% at 20 years) risk of radiation-induced second malignancies in the decades after completing radiotherapy <sup>66</sup>.

#### ***Main expert recommendations***

- Radiotherapy for patients with brain tumors should be offered only by specialized centers.
- Patient age, tumor location and prognosis should determine the choice of dose, fractionation regimens and volume.

- Prophylactic systemic steroids should not be used when initiating radiotherapy<sup>2</sup>.
- Low-to-moderate doses of dexamethasone ( $\leq 8$  mg) given in one or two daily doses should be considered in case of symptomatic brain edema or neurological deterioration during radiotherapy<sup>2</sup>.
- Transient interruption of radiotherapy may be necessary in case of intercurrent disease with or without neurological deterioration, and acute treatment toxicity should be actively managed to avoid treatment interruptions.
- Permanent discontinuation of radiotherapy should be considered only for patients with severe functional disability or unacceptable treatment toxicity.
- Prevention of late adverse events by choice of total dose, dose distribution and beam modality remains a priority because late sequelae of radiotherapy are essentially irreversible.

### **Tumor-treating fields (TTFields)**

TTFields are a non-invasive locoregional treatment modality delivering alternating electric fields with 200 kHz by a device<sup>67</sup>. Transducer arrays are localized directly on the shaved scalp of glioblastoma patients to cover the tumor bed. TTFields are contra-indicated in patients with skull defects, bullet fragments and allergy to hydrogels. The most common TTFields-related adverse events are locoregional dermatologic adverse events<sup>68</sup> i.e. dermatologic side effects beneath the transducer arrays. In a systematic review of the literature, data on safety were collected among 12 studies including 11,558 patients. The

main adverse events were skin adverse events with a pooled prevalence of 38.4%, mostly mild to moderate. Headaches were reported in 5 studies, with a pooled prevalence of 21.7%. An overview of action items for the management of dermatological toxicity is provided in Table S3. Systemic adverse events of TTFields have not been observed. In a cohort of 156 patients with ventriculoperitoneal shunt, 6 patients experienced 7 instances of TTFields therapy-related skin toxicity at the shunt site or the resection scar, but TTFields did not interfere with ventriculoperitoneal shunt function<sup>69</sup>. Datasets for the safety in association with pacemakers<sup>70</sup> or defibrillators<sup>71</sup> only contain very small sample sizes, remain inconclusive, and need validation in prospective cohorts.

### **Main expert recommendations**

- The application of TTFields with active implanted medical devices needs thorough evaluation of potential interactions. In case of simultaneous application, careful monitoring strategies are warranted.
- TTFields should be transiently interrupted for any type of dermatologic adverse events.
- TTFields should be discontinued for dermatologic ulcerations grade 3 or any indication of interference with active implanted medical devices.

## **Cancer pharmacotherapy**

### *General*

The profile of tolerance and complications of cancer pharmacotherapy for primary brain tumors differ from those used in general oncology, but some practical considerations apply (Note S1). Mode of administration and the minimum dataset of laboratory values to be considered at treatment initiation and during follow-up are provided in Table 1.

There is relatively little data on the efficacy and risks of vaccination specifically in brain tumor patients. We commonly advise to have vaccinations against influenza and COVID-19, irrespective of whether patients are undergoing treatment or not. To what extent treatments given to brain tumor patients affect the efficacy of the vaccines remains uncertain. There is increasing evidence for a risk of reactivation of viral hepatitis in patient populations at risk<sup>72</sup>. There is also increased risk of fatal systemic vaccine-associated disease with the use of yellow fever vaccine. Live vaccines are contraindicated in immunosuppressed patients. In case of previous viral disease (hepatitis), a specialized consultation should be planned.

Treatment interactions should be considered, e.g., with enzyme-inducing anti-epileptic drugs and potentially discussed with pharmacists. Complementary and alternative therapy (including herbal treatments) should be discouraged in the absence of information on potential interactions. Their use should be documented in the medical file of the patient. Further general recommendations for cancer chemotherapy and patient instruction are provided in Notes S2 and S3.

### *Steroids*

Steroids have been a mainstay in the symptomatic treatment of brain tumor patients for decades. They are mainly used to reduce the tumor-surrounding edema, which is commonly found in different types of brain tumors. By reducing mass effect, steroids provide relief from various symptoms such as headaches, nausea and many focal neurological deficits.

Dexamethasone is most frequently used with daily doses mostly in the range of 2 to 16 mg<sup>73</sup>. Despite their undisputed beneficial effects on the patients' quality of life, steroids are also associated with significant toxicities which ultimately override the positive aspects; furthermore, steroid intake may be associated with inferior survival in glioblastoma<sup>74</sup>.

Treatment with steroids is associated with increased blood sugar levels, particularly in patients with diabetes. These patients should be checked carefully for a hyperglycemic

condition that may require appropriate anti-diabetic treatment. Similarly, an increase in blood pressure may require regular controls and the initiation or adaption of antihypertensive medication. Insomnia developing during steroid intake may be prevented or reduced by administering steroids as a single dose in the morning, together with sleeping aids, if absolutely needed. Obstructive sleep apnea may develop due to the redistribution of fat. More problematic side effects that typically occur in patients with a continuous need of steroid treatment comprise gastric ulceration, rarely bowel perforation, osteoporosis with the risk of vertebral fractures, myopathy, depression and less frequently psychosis. Psychiatric disorders related to steroids need to be appropriately treated with antidepressant and neuroleptic drugs and psychiatric consultations may be required. A causative role for comedications such as levetiracetam must be considered. No specific prophylaxis other than reducing the steroid dose is available. In patients at risk for developing osteoporosis, supplementation with calcium and vitamin D formulations is frequently used in the absence of compelling evidence. Myopathy may represent a particular problem for patients with brain tumors as they are frequently affected by neurological deficits such as tumor-related paresis, ataxia and other symptoms, which may worsen because of myopathy-associated weakness. Physiotherapy may help to prevent falls and maintain quality of life. Because of an increased risk for the occurrence of pneumocystis jirovecii pneumonia (PJP), prophylactic treatment with trimethoprim-sulfamethoxazole or pentamidine inhalations should be evaluated in patients requiring steroid treatment for more than 4 weeks or those taking steroids in combination with alkylating chemotherapy or patients low lymphocyte counts <sup>75</sup>. While the interaction of steroids with immunotherapeutic agents has not yet been fully clarified, there is increasing evidence that concurrent steroid intake interferes with the anti-tumor activity of immune checkpoint inhibitors <sup>76</sup>.

In order to prevent or revert steroid-induced complications, the lowest possible dose that provides symptom control should be administered for the shortest possible time.

## *Temozolomide*

Temozolomide is an oral alkylating agent mainly used in the first-line treatment of glioblastoma and in astrocytoma, IDH-mutant, and in oligodendroglioma either as part of initial treatment or at relapse<sup>77</sup>. It is commonly given at 75 mg/m<sup>2</sup> during radiotherapy 1-2 hours before radiotherapy and in the morning prior to breakfast at 150 mg/m<sup>2</sup> for the first cycle and 200 mg/m<sup>2</sup> from the second cycle after radiotherapy (Table S4)<sup>78</sup>. The practice to administer temozolomide in the evening rather than in the morning should be discouraged, given that the clinical trial showing efficacy advised administration in the morning. Moreover, preliminary data even indicate inferior activity of temozolomide when given in the evening<sup>79</sup>.

The most common dose-limiting toxicities are hematological, notably thrombocytopenia (Table 2). Bone marrow depression occurring after weeks of daily dosing can last for several weeks, most patients recover and maintenance treatment can still be tried. The temozolomide label recommends routine prophylaxis against pneumocystis jirovecii pneumonia for all patients during concomitant treatment with RT. However, current clinical practice varies widely regarding this prophylaxis, and routine prophylaxis has been challenged in a population-based report that considered the benefit risk ratio with regard to protection from infection versus induction of myelosuppression by this prophylaxis not favorable<sup>80</sup>. Based on their analyses, these authors proposed initiating prophylaxis for patients with lymphopenia below  $0.25 \times 10^9/L$ <sup>81</sup>.

Non-hematological side effects include nausea, loss of appetite, fatigue and hepatotoxicity (Table 3). Constipation is also commonly seen in patients on temozolomide but mainly due to the concurrent use of anti-emetic agents. Proper bowel management<sup>82</sup> and reducing the dose or giving anti-emetic drugs on alternating days or even less frequently and adaptation of food may alleviate constipation. Hives associated with temozolomide are usually responsive to antihistamine drugs and commonly do not require stopping treatment.

Premedication may be considered a few days before starting the temozolomide cycle and a dermatologic consult is advised. In cases of severe allergic reactions desensitization may be considered.

Recommendations for dose modifications are compiled in Table S4. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take temozolomide. Co-administration with valproic acid was associated with a small but statistically significant decrease in the clearance of temozolomide and augments the hematological toxicity of temozolomide<sup>83</sup>. There are reports of patients who have taken the recommended dose for the 5/23 regimen for more than 5 days of treatment (up to 64 days) with adverse reactions reported including bone marrow suppression, with or without infection, in some cases severe and prolonged and resulting in death. In the event of an overdose, a hematological consultation is recommended. Supportive measures should be provided as necessary.

### Procarbazine

Procarbazine with its active metabolite benzylazoxypcarbazine is a brain penetrant oral methylating agent<sup>84</sup>. In neuro-oncology it is usually given in combination with lomustine (CCNU) and vincristine as part of the PCV regimen. The most relevant toxicities are hematological and gastrointestinal, mainly nausea and an increasing loss of appetite leading to weight loss; severe vomiting is infrequent<sup>85</sup>. A hypersensitivity rash is a frequent side effect of procarbazine (up to 25% of patients) which typically does not respond to steroids and antihistaminic agents. Because procarbazine exhibits monoaminoxidase inhibitory activity, the package inserts warns against food with high tyramine content food (wine, yoghurt, cheese, bananas). The use of procarbazine together with tricyclic antidepressants may rarely result in a serotonin syndrome that requires recognition and cessation of either



agent<sup>86</sup>. When given within the 'classical' PCV schedule, procarbazine is given on days 8 to 21 at a dose of 60 mg/m<sup>2</sup> orally<sup>87</sup>. Procarbazine dose should be dose-reduced in steps of 25% in case of hematological toxicity and in case of significant lack of appetite, asthenia and weight loss. In case of rash its use should be discontinued (Tables 2,3).

### Nitrosoureas

Nitrosoureas are a class of alkylating agents frequently used for glioma. They are highly lipid soluble and thus brain penetrant. The most well-known nitrosoureas are lomustine (CCNU), carmustine (BCNU, for i.v. use), fotemustine and nimustine (ACNU). Lomustine is the most frequently used nitrosourea<sup>88</sup>. It is part of the PCV regimen and frequently used as a single agent in recurrent glioblastoma. Lomustine is contra-indicated in case of coeliac disease or wheat allergy. Patients with hereditary galactose intolerance, total lactase deficiency or glucose galactose malabsorption should not take lomustine. A delayed and cumulative myelosuppression is the main side effect of this class of agents affecting platelets more than white blood cell count<sup>89</sup>. An interstitial pneumonitis has been described after carmustine use, but is exceedingly rare with lomustine<sup>89,90</sup>. Despite that, monitoring pulmonary function is part of the package insert. However, the absence of relevant pulmonary toxicity in lomustine-treated patients in clinical practice and in a review of toxicity data from clinical trials<sup>88,88,91</sup> does not support routine lung function monitoring in asymptomatic patients without a history of pulmonary disease. Nausea is common but mild and usually easily controlled with anti-emetics. Mild and transient serum aminotransferase elevations are frequent. Lomustine is metabolized by hepatic cytochrome P450 system, patients on enzyme inducing anti-epileptic drugs or other enzyme inducing agents should be switched to other drugs. Severe renal insufficiency is also a contra-indication to lomustine.

When given as a single agent the dose is usually 110 or 130 mg/m<sup>2</sup> in cycles of 6 weeks because of the delayed myelosuppression (Table S5). Most centers cap the dose at 200 mg.

In case of significant hematological toxicity experienced during temozolomide treatment in the first-line setting, a first lomustine cycle with a reduced dose reduction can be considered and escalation at cycle 2 if the first cycle was well tolerated.

### *Vincristine*

Vincristine belongs to the vinca alkaloid compounds and is incorporated in several polychemotherapy oncology protocols. Its most prevalent use for the treatment of primary brain tumors is in combination with procarbazine and lomustine in the PCV regimen<sup>92,93</sup>. Vincristine has a very poor oral bioavailability and is thus administered intravenously. It shows poor blood brain barrier penetration and might thus only reach contrast-enhancing tumor areas in the CNS (with a leaky blood brain barrier). The main metabolism occurs in the liver via the cytochrome enzyme system, particularly CYP3A4 and CYP3A5. Half time is around 80-85 hours, yet, interpatient variability in metabolism as well as drug drug interactions need to be considered<sup>94</sup>.

Vincristine alone is rarely myelosuppressive. Of note, its microtubulin target is also a critical component of nerve fiber axons. Thus, the main treatment-induced clinical complications are axonopathies leading to axonal sensorimotor neuropathies of large and small nerve fibers with symptoms like numbness, tingling, neuropathic pain, and hyporeflexia. Autonomic neuropathy may manifest with constipation. Risk factors for the development of vincristine-induced neuropathies include pre-existing hereditary neuropathies, and thus a corresponding family history should be considered as a contraindication for vincristine treatment. Even though preexisting vitamin deficiencies are associated with neurotoxicity, neither monitoring nor preventive vitamin supplementations are appropriate<sup>95</sup>. Since there are no standardized recommendations how to treat vincristine-induced polyneuropathy<sup>96</sup>, early recognition and cessation of vincristine exposure are essential. Medications with duloxetine, venlafaxine or baclofen might be helpful in patients with painful neuropathy.

## Bevacizumab

Bevacizumab is a recombinant humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor (VEGF)-A. Its mode of actions includes reduced vessel leakiness and intratumoral pressures, as well as vessel regression. The reduction of vasogenic edema results in corticosteroid-sparing effects. The standard dose for glioblastoma per label is 10 mg/kg, but de-escalation to 7.5 or 5 mg/kg and prolonged dosing intervals can be considered on an individual basis. The half time is in the range of 18-21 days, thus infusions are given every 14-21 days depending on the regimen. Bevacizumab prolongs progression-free survival but not overall survival in newly diagnosed and progressive glioblastoma and has been approved for recurrent glioblastoma in the USA, Switzerland, and Japan, although not by the European Medicines Agency.

The most common side effects with bevacizumab are hypertension, hoarseness, fatigue or asthenia, diarrhoea and abdominal pain, and proteinuria. The most serious side effects are gastrointestinal perforation, hemorrhage, impaired wound healing and arterial thromboembolism.

The management of bevacizumab-related adverse events included prolongation of infusion intervals (up to eight weeks) and/or discontinuation (if the interval exceeded eight weeks). Further relevant aspects for clinical management are wound healing, thus a latency of 28 days (i.e. exceeding one half time of the drug) before/after major surgical interventions should be considered. No guidelines are available regarding bevacizumab in case of elective minor surgery (dental surgery, central venous access). A wound dehiscence was noted in 6 of 195 patients (3%) receiving bevacizumab within 10 days of port placement<sup>97</sup>. Treatment adjustments after adverse events are recapitulated in Table 3.

## Targeted therapy

### BRAF

A BRAF V600E mutation is present in 3-4% of gliomas, for which treatment with BRAF inhibitors (eg, vemurafenib) alone or combined with MEK inhibition, e.g., trametinib with dabrafenib, may be effective<sup>98,99</sup>. The addition of a MEK inhibitor to BRAF inhibition improves the blockade of the mitogen-activated protein kinase pathway which mitigates acquired resistance against BRAF monotherapy and reduces the incidence of skin-related toxicities of BRAF inhibition, in particular verrucal keratosis<sup>100</sup>. Vemurafenib is associated with arthralgias and skin toxicity in more than half of the patients, and with photosensitivity in 40%. It is given at a dose of 960 mg twice per day continuously in 28-day cycles, with dose reductions on the basis of toxicity in decrements of 240 mg at each dose administration<sup>98</sup>. The skin toxicity requires avoidance of sun exposure and use of sunblocks. Combination treatment dabrafenib (150 mg twice daily) and trametinib (2 mg once daily orally) is associated with mild fatigue (40%), nausea and vomiting (30%), pyrexia (30%) and rash (30%); nasopharyngitis, constipation and arthralgias are also relatively frequent but mild<sup>99</sup>. Neutropenia grade 3 may occur in 10%. The combination is given at a starting dose of 150 mg orally twice daily and 2 mg orally once daily respectively, with dose reductions and delays in case of toxicities. Cardiac monitoring is required (see below, Table 3). Given the frequent requirements for the management of pyrexia and the rarity of BRAF mutations, treatment should be done in collaboration with a specialist with experience in these agents<sup>101,102</sup>.

### NTRK

Oncogenic fusions of the neurotrophic tyrosine receptor kinase (*NTRK*) genes NTRK1, NTRK2, and NTRK3 are observed with various gene partners and oncogenic drivers<sup>103</sup>. Among adults with primary brain tumors, NTRK fusions are reported with a frequency of 1-2%<sup>104,105</sup> and are most frequently found in glioblastoma.

Larotrectinib and entrectinib represent the first generation of NTRK inhibitors and are approved by FDA and EMA in TRK fusion-positive cancers. Fatigue, liver enzyme increases, cough, constipation, diarrhea, dysgeusia, dizziness, nausea and vomiting have been reported in more than 20% of patients in the larotrectinib trials<sup>106,107</sup>. The most frequent adverse events reported in the entrectinib trials include weight gain, arthralgia and myalgia, dysgeusia, dyesthesia and peripheral sensitive neuropathies, dizziness and ataxia, fatigue, constipation, diarrhoea, peripheral oedema nausea and vomiting<sup>107,108</sup>. Risks of congestive heart failure, QTc prolongation, fractures have to be considered with entrectinib. Proposed assessment before treatment initiation and during follow-up are described in Table 1. Second generation drugs such as selitrectinib and repotrectinib are currently evaluated in clinical trials. Adverse reactions may require temporary interruption, dose reduction, or discontinuation. Concomitant use of strong or moderate CYP3A inhibitors increases entrectinib plasma concentrations whereas strong or moderate CYP3A inducers may decrease entrectinib plasma concentrations. Concomitant medication should be regularly monitored.

### ***Main expert recommendations***

- For young adults, both females and males, specialized consultation should be offered to discuss fertility and potential solutions prior to initiation of systemic pharmacotherapy<sup>109</sup>.
- The relevance of an adequate contraception should be discussed with both male and non-menopausal female patients before treatment initiation. Pregnancy tests should performed in case of any doubt on a potential pregnancy before and during the conduct of the systemic pharmacotherapy<sup>109</sup>.
- Systemic pharmacotherapy should commonly not be given unless neutrophil counts are > 1,500/ $\mu$ L and platelet counts > 100,000/ $\mu$ L.

- Pharmacological interactions, notably with anti-epileptic drugs, should be considered when initiating pharmacotherapy for any brain tumor.
- Complementary and alternative therapy (including herbal treatments) should be discouraged, especially during systemic pharmacotherapy, and always documented in the patient charts.
- Systemic pharmacotherapy should commonly not be given when aspartate aminotransferase and alanine aminotransferase levels are elevated three-fold or more.
- Pulmonary function should be checked prior to nitrosourea therapy in patients with chronic pulmonary disease.
- Vincristine should be stopped upon the first symptoms or signs of polyneuropathy and re-exposure is not advised.
- Cardiac monitoring, including ECG and left ventricular ejection fraction evaluation, is required before and during treatment with BRAF and NTRK inhibitors.
- Comedication should be taken into account notably for NTRK inhibitors.

### **Cancer pharmacotherapy – management of side effects by organ site**

#### **Hematological toxicity (Table S6)**

##### Neutropenia

The decrease of the neutrophil count below normal is the most common side effect of the chemotherapeutic agents used in primary brain tumors. The agents used in gliomas, temozolomide, lomustine and less so procarbazine frequently cause neutropenia, as can etoposide, carboplatin and cyclophosphamide which are used in other primary brain tumors. Grading of neutropenia is based on the CTCAE scale <sup>1</sup> and dose adjustments for subsequent cycles are performed according to the grading of toxicity. Of note, subsequent

myelotoxic chemotherapy regimens may need to be initiated at reduced dose if significant myelotoxicity has occurred during prior treatments.

Absolute neutrophil counts below 500 / $\mu$ L increase the risk of infection and thus febrile neutropenia, hospitalization and mortality, and this risk increases with longer duration of neutropenia. Since therapy reintroduction is recommended only after the absolute neutrophil count has recovered to > 1,500/ $\mu$ L depending on the patient and chemotherapy agent, prolonged neutropenia causes dose delays and dose reductions, possibly affecting efficacy.

For these reasons the use of recombinant growth colony stimulating factors (G-CSF) is indicated when the risk of febrile neutropenia is higher than 20% or when significant dose reductions and delays occur, or for febrile neutropenia risk of >10% in patients > 65 years of age or patients with serious comorbidities. Risk calculation can be done using special models such as the Multinational Association for Supportive Care in Cancer (MASCC) model<sup>110</sup> or by the use of the National Comprehensive Cancer Network (NCCN) guidelines<sup>111</sup>.

The risk of febrile neutropenia increases with age and is influenced by co-morbidities of the patient, the chemotherapeutic agents used, the number of previous lines of therapy, and the fields of prior radiotherapy<sup>112</sup>. Depending upon the indication for chemotherapy, curative versus palliative, G-CSF prophylaxis may be considered to maintain dose intensity, but this rarely applies to patients with primary brain tumors.

### Lymphopenia

Lymphopenia is a relatively frequent complication of temozolomide, and less so of other chemotherapy agents used in neuro-oncology. A very low CD4 count (< 200 / $\mu$ L), considered absolute lymphopenia, may be encountered, thus predisposing patients to opportunistic infections such as pneumocystis jirovecii pneumonia or viral infections such as cytomegalovirus<sup>113</sup>. These risks are aggravated by the chronic use of steroids and the use

of radiotherapy. Thus patients with primary brain tumors are prone to these infections and many centers use prophylactic trimethoprim (80-160 mg orally daily or 160 mg 3-times/week on alternate days)/sulfamethoxazole (800 mg) during radiotherapy (even in the absence of concomitant steroids) <sup>114</sup>. Alternatively, regular testing of CD4 counts may permit the use of this prophylaxis only when counts drop below 200/ $\mu$ L <sup>114</sup>. The discontinuation of prophylaxis is dependent both on the counts and on other parameters such as the use and tapering of steroids. Clinician awareness of these complications is of paramount importance so that diagnosis of pneumocystis pneumonia is made and therapy is initiated promptly.

In patients with an allergy to trimethoprim/sulfamethoxazole or G6PD deficiency, close observation can be used although an alternative is inhaled pentamidine or atovaquone <sup>115</sup>.

Although some centers consider antiviral prophylaxis, there is no evidence for its activity so we do not recommend this. No measures can ensure that CD4 counts will rise, nor is dose adjustment advised for this complication. Since higher dose and dose-intensive regimens of temozolomide cause more lymphopenia, their use is discouraged, as should be the use of corticosteroids without clear rationale.

### Thrombocytopenia

During concomitant radiotherapy and temozolomide in patients newly diagnosed with a glioblastoma thrombocytopenia of any CTCAE grade is observed in more than 25% and grade 3/4 thrombocytopenia in 5% which may last for several weeks. During maintenance temozolomide, thrombocytopenia any grade is reported in 45% and grade 3/4 in 7% <sup>116</sup>. In the first recurrence setting, thrombocytopenia of any grade was noted in 26% of patients treated with lomustine alone and in 33% of patients treated with both lomustine and bevacizumab <sup>117</sup>. In the EORTC 26951 trial, grade 3 or 4 thrombocytopenia was noted in 21% of patients treated with PCV after radiotherapy <sup>87</sup>.



Thrombocytopenia is associated with a risk of cerebral and extra-CNS hemorrhage, chemotherapy dose reductions, dose delays, or discontinuation. Most institutional recommendations and clinical trial protocols state that a platelet count of  $100 \times 10^3/\mu\text{L}$  is required for the continuation of chemotherapy and that CTCAE grade 3 or 4 toxicities should trigger a reduction of chemotherapy to the next lower dose level. Prophylactic platelet transfusions should be administered if platelet counts are below  $10\text{-}20 \times 10^3/\mu\text{L}$ , or between  $20 \times 10^3/\mu\text{L}$  and  $50 \times 10^3/\mu\text{L}$  in the presence of bleeding events, such as exteriorizing bleeding, hematoma, or petechiae, as per ASCO guidelines <sup>118</sup>. Simple recommendations such as avoiding the use of sharp object (steak knife), avoiding sports at risk, avoiding food associated with a risk of obstipation, using soft toothbrush or mouthwash, and using an adapted toothpaste should be provided. In case of drug re-exposure after dose/schedule modification or discontinuation for thrombocytopenia, a weekly platelet count should be performed. The thrombopoietin receptor agonist, romiplostim, may allow to complete a course of alkylating chemotherapy if thrombocytopenia is the main limiting toxicity <sup>119</sup>, however, further data are needed.

### Anemia

Anemia may be caused by the use of chemotherapy, including the agents used in primary CNS tumors, mainly temozolomide, procarbazine and lomustine, as well as the platinum agents and cyclophosphamide used in ependymoma and medulloblastoma. In cases where anemia is sudden or unexplained, a work up to rule out other causes of anemia such as blood loss, hemolysis or renal failure should be performed.

If hemoglobin levels drop below 8 g/dL, blood transfusion is indicated <sup>120</sup>. This level of hemoglobin may be different in patients with co-morbidities such as pulmonary, cerebrovascular or cardiac disease or in patients who are symptomatic with severe fatigue, arrhythmia, chest pain or dyspnea.

Most primary brain tumors that are treated with chemotherapy are not treated with curative intent. In such cases the use of erythropoiesis-inducing agents, where available, may be used to avoid transfusions. Of note, these agents are used to prevent anemia more than to treat it, as it may take weeks for an erythropoiesis-inducing agent to correct anemia while a transfusion will correct it immediately. The usual cut off for introducing such agents is a hemoglobin of 10 g/dL, but lower threshold levels may be used to reduce cost and the risk of side effects. The goal should be a hemoglobin level that does not require transfusion and once this goal is achieved or a rise of 1 g/dL of hemoglobin in 2 weeks is detected, the dose of the erythropoiesis-inducing agent can be reduced by 40% in the case of darbepoetin and 25% for epoetin alpha, as the level of hemoglobin should not surpass 12 g/dL.

Concerns that signaling via the EPO receptor expressed on tumor cells may promote tumor progression have not been substantiated <sup>121</sup>. The use of erythropoiesis-inducing agents may be appropriate to improve quality of life since tumor-promoting claims have not been substantiated <sup>122</sup>. Anemia is usually not a reason to decrease the dose of, or to withhold, chemotherapy, but dose reduction should be considered usually if transfusions are required repeatedly.

Of note, erythropoietin use may increase the risk of thrombosis as can transfusions, a side effect of importance in immobilized brain tumor patients <sup>123</sup>. Lastly erythropoiesis-inducing agents may cause arterial hypertension <sup>124</sup>, a particularly relevant side effect in patients on steroids or bevacizumab.

## Non-hematological toxicity

### *Skin*

Cutaneous adverse drug reactions are infrequent in patients with primary brain tumors receiving anti-tumor therapy. Skin toxicity is rare with temozolomide whereas procarbazine may cause allergy and occasionally toxic epidermal necrosis<sup>125 126</sup> which requires cessation of the drug. Furthermore, skin irritations are common but mostly mild in patients who are using TTFields<sup>127</sup>. Targeted therapies can cause skin reactions ranging from mild skin rash to life-threatening severe cutaneous adverse reactions such as Stevens-Johnson syndrome, toxic epidermal necrosis and the hand-foot skin reaction (HFSR). This toxicity may reflect direct skin toxicity or drug hypersensitivity reactions. Patients treated with BRAF inhibitors may experience photosensitivity and maculopapular eruptions. The same type of cutaneous adverse drug reactions is commonly seen in patients treated with NTRK inhibitors such as larotrectinib<sup>128</sup> or entrectinib<sup>108</sup>, particularly cutaneous rash and photosensitivity reactions. Measures for the prevention of HFSR include the removal of preexisting hyperkeratotic areas or calluses and the use of shoe cushions and gloves to prevent pressure-induced stress to soles and palms. Once diagnosed, the management of HFSR includes the use of keratolytic and moisturizing creams for symptomatic relief. In case of severe or persistent symptoms, dose reductions as well as temporary or permanent treatment interruption must be considered.

### *Lung*

Pulmonary toxicity is a known complication associated with the use of nitrosoureas.

Treatment with carmustine (BCNU) bears a risk for the development of pulmonary fibrosis which occurs within weeks to months after treatment in up to 30% of patients. In rare cases in adult patients with brain tumors, late manifestations of lung fibrosis have been reported<sup>129</sup>. Younger age and higher nitrosourea doses are associated with an increased risk for

pulmonary fibrosis. For carmustine, doses beyond 1,500 mg/m<sup>2</sup> in adults should be avoided. The incidence of pulmonary toxicity in glioma trials is overall very low <sup>130</sup> perhaps because of the routine use of lomustine which harbors a lower risk for pulmonary toxicity than carmustine <sup>91</sup>.

Infections, such as bronchitis, lower respiratory tract infection or pneumonia are diagnosed in approximately 10-15% of adult and pediatric patients treated with NTRK inhibitors. Patients who are treated with dabrafenib in combination with trametinib have a risk for the development of interstitial lung disease or pneumonitis <sup>131</sup>. Currently, no dose modification of dabrafenib is recommended when taken in combination with trametinib for cases of interstitial lung disease or pneumonitis, but treatment should be halted until full recovery from clinical symptoms and re-exposure is not advised <sup>132</sup>. Furthermore, cases of sarcoidosis have been reported in patients receiving dabrafenib and trametinib, mostly involving the skin, lung, eye and lymph nodes.

### *Liver*

Hepatic toxicity has been reported for temozolomide and may include increased liver enzymes, hyperbilirubinaemia and cholestasis <sup>133</sup>. Monitoring liver function before and during temozolomide treatment, e.g., 4-8 weeks, is recommended. Abnormal liver function tests should trigger the exclusion of changes in coagulation parameters. Furthermore, HCV infection should be ruled out by virus serology and abdominal sonography should be obtained to confirm that TMZ is the main cause of liver dysfunction. Laboratory abnormalities should be managed with dose reductions, treatment interruption or discontinuation. Meulengracht's disease is no contraindication for chemotherapy. Advice from hepatology experts should be sought before potentially active anti-tumor treatment is halted or discontinued.

Elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values are common findings patients receiving NTRK inhibitors, mostly occurring in the first 3 months of treatment. Interruption or discontinuation of these drugs should be considered depending on the severity of the liver injury. For BRAF inhibitors, liver toxicity, sometimes severe, has been reported<sup>131</sup>. For antiangiogenic drugs, especially regorafenib, liver function abnormalities have been frequently observed. Therefore, it is recommended to perform liver function tests before initiation of treatment and to monitor these parameters closely. Mild, indirect (unconjugated) hyperbilirubinemia may occur in patients with Gilbert's syndrome and is no contraindication for chemotherapy. Similar to other drugs which exert liver toxicity, dose modification as well as treatment interruption or discontinuation have to be considered.

### *Kidney*

Among classical chemotherapeutic agents used in brain tumor patients, platinum-based drugs have a well known risk to exert renal toxicity. Nephrotoxicity is more frequently associated with the use of cisplatin compared to carboplatin and elderly patients are more likely to suffer from renal toxicity<sup>134</sup>. Treatment with bevacizumab may result in renal thrombotic microangiopathy which may manifest as proteinuria<sup>135</sup>. The severity of the latter may range from clinically asymptomatic, transient, trace proteinuria to nephrotic syndrome. Grade 3 proteinuria was reported in up to 10.9% of treated patients. Grade 4 proteinuria (nephrotic syndrome) was observed in 1.4% of treated patients. Testing for proteinuria is recommended prior to the initiation and before each administration of bevacizumab therapy. This can be done by screening using a dipstick first and in case of 2+ a 24 hours urine analysis. In clinical trials, urine protein levels of  $\geq 2$ -3 g/24 h led to the holding of bevacizumab until recovery to  $< 2$  g/24 h. Proteinuria has been reported rarely in patients treated with regorafenib. Cases of renal toxicity have also been reported upon treatment with

vemurafenib ranging from creatinine elevations to acute interstitial nephritis and acute tubular necrosis. Serum creatinine elevations were mostly mild ( $>1$ - $1.5\times$  ULN) to moderate ( $>1.5$ - $3\times$  ULN) and usually reversible.

### *Cardio-vascular*

Dose-dependent arterial hypertension has been observed in bevacizumab-treated patients<sup>136,137</sup>. Pre-existing hypertension should be adequately controlled before starting bevacizumab treatment and monitoring of blood pressure values is recommended during therapy. Bevacizumab should be permanently discontinued if significant arterial hypertension cannot be adequately controlled with antihypertensive therapy, or if the patient develops hypertensive crisis or hypertensive encephalopathy.

Syncope was reported in 5% of patients treated with NTRK inhibitors, sometimes associated with arterial hypotension, dehydration, or QTc prolongation. Similarly, QTc prolongation may also occur in patients treated with BRAF inhibitors<sup>131</sup>. QTc prolongation may lead to an increased risk of ventricular arrhythmias including *Torsade de Pointes*. Therefore, treatment with these drugs is not recommended in patients with uncorrectable electrolyte abnormalities, including magnesium, long QT syndrome or in patients taking other drugs which may prolong the QTc interval. Electrocardiogram (ECG) and electrolytes must be monitored in all patients before and during treatment with BRAF inhibitors. Moreover, if QTc exceeds 500 ms, BRAF inhibitor treatment should be temporarily interrupted. Regorafenib has been associated with an increased incidence of myocardial ischemia and infarction. Therefore, patients with a history of ischemic heart disease should be monitored for clinical signs and symptoms of myocardial ischemia.

## *Gastrointestinal*

Gastrointestinal side effects are frequent in patients receiving treatment with classical alkylating agents such as temozolomide, procarbazine or nitrosoureas. Nausea and vomiting have been reported in 50% of patients or more, depending on the dose and schedule <sup>138</sup>. Appropriate prophylaxis with antiemetics such as 5HT<sub>3</sub>-receptor antagonists or other drugs will prevent nausea and vomiting in the majority of patients <sup>139</sup>. In turn, 5HT<sub>3</sub>-receptor antagonists harbor a risk for the development of constipation, which may require appropriate dietary changes or treatment with laxatives. Of note, 5HT<sub>3</sub> receptor antagonists can prolong the QTc interval.

Patients treated with bevacizumab have an increased risk of gastrointestinal perforation. In such cases, therapy should be permanently discontinued. Most targeted agents frequently exert gastrointestinal side effects such as diarrhea, mostly of mild to moderate intensity. Diarrhoea, nausea and vomiting are commonly seen during therapy with BRAF and MEK inhibitors and can be accompanied by abdominal pain and gastrointestinal bleeding <sup>131</sup>.

## *CNS*

Neurocognitive impairment is frequently diagnosed in brain tumor patients <sup>140</sup>. Beyond direct damage caused by the tumor and sequelae of surgery and radiotherapy, many chemotherapy as well as targeted anti-cancer drugs may contribute to undesired effects, also referred to as "chemobrain", but this syndrome plays almost no role in patients with primary brain tumors. Currently, no specific measures are available to prevent this condition. There have been reports of bevacizumab<sup>141</sup> and regorafenib<sup>142</sup> treated patients developing posterior reversible encephalopathy syndrome (PRES), a rare neurologic disorder which may present with seizures, headache, altered mental status, visual disturbance, or cortical blindness, with or without associated hypertension. PRES is diagnosed based on typical clinical and MRI findings. Other reasons for the observed clinical symptoms and signs need to be ruled out. In patients developing PRES, symptomatic treatment of seizures and

antihypertensive therapy as needed are recommended along with discontinuation of the causative agent. The safety of reinitiating antiangiogenic therapy in patients previously experiencing PRES is not known.

### *Fertility*

Chemotherapy, particularly alkylating agents, can cause infertility in men and women, the older the patient the higher the risk of infertility, particularly for women over 40 years old. This issue is especially important for young patients with favorable prognosis or potentially curable brain tumors. As chemotherapy-induced infertility cannot be prevented, measures should be taken for fertility preservation. A few studies have shown benefit from the use of luteinizing hormone releasing hormone (LHRH) analogs during chemotherapy in young women thus inducing a state of dormancy in the ovaries, preventing gonad toxicity from chemotherapy<sup>143</sup>. Furthermore, sperm banking for men and oocyte, embryo or ovarian tissue cryopreservation may be an option for patients before the start of chemotherapy<sup>144</sup>, for example, in medulloblastoma during the radiotherapy phase or prior to treatment in patients with oligodendroglioma and astrocytoma, IDH mutant. Embryo cryopreservation is a well known technique, oocyte cryopreservation is more recent and unstimulated ovarian tissue cryopreservation has started being used<sup>145 146</sup>. The collection of oocytes usually requires hormonal stimulation. In most countries a legal framework addressing ownership issues controls the *ex vivo* fertilization of oocytes<sup>147</sup>. Infertility can also be a result of hypophyseal insufficiency caused by radiotherapy and in very rare cases by inadvertent radiation to the ovaries during neuraxis radiotherapy. For the former endocrine evaluation is of paramount importance. For the latter, in the rare occasions where the patient's body habitus is such that the field may involve the ovaries, the solution is oophoropexy which is the transposition of the ovaries before RT to protect them from the radiotherapy<sup>148</sup>. Therefore radiotherapists need to assess this while designing the field and act accordingly.



## ***Main expert recommendations***

- Absolute neutrophil counts below 500/ $\mu$ L should trigger antibiotic prophylaxis and consideration of treatment with G-CSF.
- A CD4 T-cell count below 200/ $\mu$ L should trigger prophylaxis with trimethoprin sulfamethoxazole and acyclovir.
- Thrombocytopenia below 10-20 $\times 10^3$ / $\mu$ L should be treated with platelet transfusions.
- Red blood cell transfusions should be considered when hemoglobin levels fall below 8 g/ $\mu$ L.
- Patients with a history of cardiopulmonary disease should undergo lung functional testing prior to treatment with nitrosourea.
- Dose reductions or discontinuation of cancer pharmacotherapy need to be considered for patients with severe or recurrent hepatotoxicity.
- Counselling for fertility should be offered for most women and men prior to the start of cancer pharmacotherapy.

## ***Conclusions***

The quality of patient management and care depends to a relevant degree on how adverse events of therapy are recognized, managed and prevented. Neuro-oncologists should consider working closer with palliative care specialists and symptom management services to be proactive in addressing side effects of cancer therapy. The present recommendations represent a contemporary consensus.

Patterns of managing and responding to toxicity with changes in the treatment regimen may vary significantly across the globe. However, we believe that this article may represent a first important step to harmonize this hitherto somewhat neglected field of neuro-oncology.

## References

1. Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. Accessed January 30, 2022.  
[https://ctep.cancer.gov/protocolDevelopment/electronic\\_applications/ctc.htm](https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm)
2. Roth P, Pace A, Le Rhun E, et al. Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. *Ann Oncol*. 2021;32(2):171-182.  
doi:10.1016/j.annonc.2020.11.003
3. Dickinson H, Carico C, Nuño M, et al. Unplanned readmissions and survival following brain tumor surgery. *J Neurosurg*. 2015;122(1):61-68. doi:10.3171/2014.8.JNS1498
4. Barach P, Small SD. Reporting and preventing medical mishaps: lessons from non-medical near miss reporting systems. *BMJ*. 2000;320(7237):759-763.  
doi:10.1136/bmj.320.7237.759
5. Landriel Ibañez FA, Hem S, Ajler P, et al. A new classification of complications in neurosurgery. *World Neurosurg*. 2011;75(5-6):709-715; discussion 604-611.  
doi:10.1016/j.wneu.2010.11.010
6. Schiavolin S, Broggi M, Acerbi F, et al. The Impact of Neurosurgical Complications on Patients' Health Status: A Comparison Between Different Grades of Complications. *World Neurosurg*. 2015;84(1):36-40. doi:10.1016/j.wneu.2015.02.008
7. Hauser A, Dutta SW, Showalter TN, Sheehan JP, Grover S, Trifiletti DM. Impact of academic facility type and volume on post-surgical outcomes following diagnosis of glioblastoma. *J Clin Neurosci*. 2018;47:103-110. doi:10.1016/j.jocn.2017.10.087
8. Mahato D, De Biase G, Ruiz-Garcia HJ, et al. Impact of facility type and volume on post-surgical outcomes following diagnosis of WHO grade II glioma. *J Clin Neurosci*. 2018;58:34-41. doi:10.1016/j.jocn.2018.10.078
9. Berger A, Tzarfaty G, Costa M, et al. Incidence and impact of stroke following surgery for low-grade gliomas. *J Neurosurg*. Published online December 27, 2019:1-9.  
doi:10.3171/2019.10.JNS192301
10. Thielpold AL, Luger S, Wagner M, et al. Perioperative cerebral ischemia promote infiltrative recurrence in glioblastoma. *Oncotarget*. 2015;6(16):14537-14544.  
doi:10.18632/oncotarget.3994
11. Gempt J, Förschler A, Buchmann N, et al. Postoperative ischemic changes following resection of newly diagnosed and recurrent gliomas and their clinical relevance. *J Neurosurg*. 2013;118(4):801-808. doi:10.3171/2012.12.JNS12125
12. Etgen T, Steinich I, Gsottschneider L. Thrombolysis for ischemic stroke in patients with brain tumors. *J Stroke Cerebrovasc Dis*. 2014;23(2):361-366.  
doi:10.1016/j.jstrokecerebrovasdis.2013.05.004
13. Berkhemer OA, Fransen PSS, Beumer D, et al. A randomized trial of intraarterial

treatment for acute ischemic stroke. *N Engl J Med*. 2015;372(1):11-20.  
doi:10.1056/NEJMoa1411587

14. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med*. 2015;372(11):1019-1030.  
doi:10.1056/NEJMoa1414905

15. Wong JM, Panchmatia JR, Ziewacz JE, et al. Patterns in neurosurgical adverse events: intracranial neoplasm surgery. *Neurosurg Focus*. 2012;33(5):E16.  
doi:10.3171/2012.7.FOCUS12183

16. Barkley AS, Sullivan LT, Gibson AW, et al. Stereotactic Brain Biopsy Hemorrhage Risk Factors and Implications for Postoperative Care at a Single Institution: An Argument For Postoperative Imaging. *World Neurosurg*. 2020;144:e807-e812.  
doi:10.1016/j.wneu.2020.09.084

17. Liu W, Qdaisat A, Yeung J, et al. The Association Between Common Clinical Characteristics and Postoperative Morbidity and Overall Survival in Patients with Glioblastoma. *Oncologist*. 2019;24(4):529-536. doi:10.1634/theoncologist.2018-0056

18. Wang YC, Lee CC, Takami H, et al. Awake craniotomies for epileptic gliomas: intraoperative and postoperative seizure control and prognostic factors. *J Neurooncol*. 2019;142(3):577-586. doi:10.1007/s11060-019-03131-0

19. Zanello M, Roux A, Zah-Bi G, et al. Predictors of early postoperative epileptic seizures after awake surgery in supratentorial diffuse gliomas. *J Neurosurg*. 2020;134(3):683-692. doi:10.3171/2020.1.JNS192774

20. Youngerman BE, Joiner EF, Wang X, et al. Patterns of seizure prophylaxis after oncologic neurosurgery. *J Neurooncol*. 2020;146(1):171-180. doi:10.1007/s11060-019-03362-1

21. Walbert T, Harrison RA, Schiff D, et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. *Neuro Oncol*. 2021;23(11):1835-1844. doi:10.1093/neuonc/noab152

22. Clark AJ, Butowski NA, Chang SM, et al. Impact of bevacizumab chemotherapy on craniotomy wound healing. *J Neurosurg*. 2011;114(6):1609-1616.  
doi:10.3171/2010.10.JNS101042

23. Abrams DA, Hanson JA, Brown JM, Hsu FPK, Delashaw JB, Bota DA. Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma. *J Clin Neurosci*. 2015;22(1):35-39. doi:10.1016/j.jocn.2014.05.054

24. Dashti SR, Baharvahdat H, Spetzler RF, et al. Operative intracranial infection following craniotomy. *Neurosurg Focus*. 2008;24(6):E10. doi:10.3171/FOC/2008/24/6/E10

25. Maye H, Colombo F, Bourama E, et al. Does the Use of Surgical Adjuncts Affect Postoperative Infection Rates in Neuro-oncology Surgery? *World Neurosurg*. 2022;162:e246-e250. doi:10.1016/j.wneu.2022.02.124

26. De Bonis P, Albanese A, Lofrese G, et al. Postoperative infection may influence

survival in patients with glioblastoma: simply a myth? *Neurosurgery*. 2011;69(4):864-868; discussion 868-869. doi:10.1227/NEU.0b013e318222adfa

27. Davies BM, Jones A, Patel HC. Implementation of a care bundle and evaluation of risk factors for surgical site infection in cranial neurosurgery. *Clin Neurol Neurosurg*. 2016;144:121-125. doi:10.1016/j.clineuro.2016.03.025

28. Rubeli SL, D'Alonzo D, Mueller B, et al. Implementation of an infection prevention bundle is associated with reduced surgical site infections in cranial neurosurgery. *Neurosurg Focus*. 2019;47(2):E3. doi:10.3171/2019.5.FOCUS19272

29. Mann M, Wright CH, Jella T, et al. Cranial Surgical Site Infection Interventions and Prevention Bundles: A Systematic Review of the Literature. *World Neurosurg*. 2021;148:206-219.e4. doi:10.1016/j.wneu.2020.12.137

30. Fischer CM, Neidert MC, Péus D, et al. Hydrocephalus after resection and adjuvant radiochemotherapy in patients with glioblastoma. *Clin Neurol Neurosurg*. 2014;120:27-31. doi:10.1016/j.clineuro.2014.02.012

31. Marx S, Reinfelder M, Matthes M, Schroeder HWS, Baldauf J. Frequency and treatment of hydrocephalus prior to and after posterior fossa tumor surgery in adult patients. *Acta Neurochir (Wien)*. 2018;160(5):1063-1071. doi:10.1007/s00701-018-3496-x

32. Mallucci CL, Jenkinson MD, Conroy EJ, et al. Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multicentre, single-blinded, randomised trial and economic evaluation. *Lancet*. 2019;394(10208):1530-1539. doi:10.1016/S0140-6736(19)31603-4

33. Minniti G, Goldsmith C, Brada M. Radiotherapy. *Handb Clin Neurol*. 2012;104:215-228. doi:10.1016/B978-0-444-52138-5.00016-5

34. Rosenthal A, Israilevich R, Moy R. Management of acute radiation dermatitis: A review of the literature and proposal for treatment algorithm. *J Am Acad Dermatol*. 2019;81(2):558-567. doi:10.1016/j.jaad.2019.02.047

35. Anker CJ, Grossmann KF, Atkins MB, Suneja G, Tarhini AA, Kirkwood JM. Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). *Int J Radiat Oncol Biol Phys*. 2016;95(2):632-646. doi:10.1016/j.ijrobp.2016.01.038

36. Bishop AJ, Chang M, Lacouture ME, Barker CA. EMPACT syndrome: limited evidence despite a high-risk cohort. *J Neurooncol*. 2014;119(1):129-134. doi:10.1007/s11060-014-1457-7

37. Gauter-Fleckenstein B, Israel CW, Dorenkamp M, et al. DEGRO/DGK guideline for radiotherapy in patients with cardiac implantable electronic devices. *Strahlenther Onkol*. 2015;191(5):393-404. doi:10.1007/s00066-015-0817-3

38. Razvi Y, Chan S, McFarlane T, et al. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. *Support Care Cancer*. 2019;27(1):87-95. doi:10.1007/s00520-018-4464-y

39. de Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2010;21 Suppl 5:v252-256. doi:10.1093/annonc/mdq196
40. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*. 2015;33(28):3199-3212. doi:10.1200/JCO.2015.62.3488
41. The Royal College of Radiologists, www.rcr.ac.uk. The timely delivery of radical radiotherapy: guidelines for the management of unscheduled treatment interruptions - fourth edition.
42. Kyriakakis N, Lynch J, Orme SM, et al. Hypothalamic-pituitary axis irradiation dose thresholds for the development of hypopituitarism in adult-onset gliomas. *Clin Endocrinol (Oxf)*. 2019;91(1):131-140. doi:10.1111/cen.13971
43. Wick W, Chinot OL, Bendszus M, et al. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. *Neuro Oncol*. 2016;18(10):1434-1441. doi:10.1093/neuonc/now091
44. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. *J Clin Oncol*. 2008;26(13):2192-2197. doi:10.1200/JCO.2007.14.8163
45. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. *N Engl J Med*. 2014;370(8):709-722. doi:10.1056/NEJMoa1308345
46. Lawrence YR, Li XA, el Naqa I, et al. Radiation dose-volume effects in the brain. *Int J Radiat Oncol Biol Phys*. 2010;76(3 Suppl):S20-27. doi:10.1016/j.ijrobp.2009.02.091
47. Minniti G, Niyazi M, Alongi F, Navarria P, Belka C. Current status and recent advances in reirradiation of glioblastoma. *Radiat Oncol*. 2021;16(1):36. doi:10.1186/s13014-021-01767-9
48. Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. *Int J Radiat Oncol Biol Phys*. 2011;79(5):1487-1495. doi:10.1016/j.ijrobp.2009.12.061
49. Chung C, Bryant A, Brown PD. Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery. *Cochrane Database Syst Rev*. 2018;7:CD011492. doi:10.1002/14651858.CD011492.pub2
50. Makale MT, McDonald CR, Hattangadi-Gluth JA, Kesari S. Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours. *Nat Rev Neurol*. 2017;13(1):52-64. doi:10.1038/nrneurol.2016.185
51. Jalali R, Gupta T, Goda JS, et al. Efficacy of Stereotactic Conformal Radiotherapy vs Conventional Radiotherapy on Benign and Low-Grade Brain Tumors: A Randomized Clinical



Trial. *JAMA Oncol.* 2017;3(10):1368-1376. doi:10.1001/jamaoncol.2017.0997

52. Saraf A, Yock TI, Niemierko A, et al. Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: a contemporary single-institution experience. *Neuro Oncol.* Published online June 7, 2022: noac126. doi:10.1093/neuonc/noac126
53. Cayuela N, Jaramillo-Jiménez E, Càmarà E, et al. Cognitive and brain structural changes in long-term oligodendroglial tumor survivors. *Neuro Oncol.* 2019;21(11):1470-1479. doi:10.1093/neuonc/noz130
54. Jacob J, Durand T, Feuvret L, et al. Cognitive impairment and morphological changes after radiation therapy in brain tumors: A review. *Radiother Oncol.* 2018;128(2):221-228. doi:10.1016/j.radonc.2018.05.027
55. Jaspers J, Mèndez Romero A, Hoogeman MS, et al. Evaluation of the Hippocampal Normal Tissue Complication Model in a Prospective Cohort of Low Grade Glioma Patients- An Analysis Within the EORTC 22033 Clinical Trial. *Front Oncol.* 2019;9:991. doi:10.3389/fonc.2019.00991
56. Gondi V, Hermann BP, Mehta MP, Tomé WA. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. *Int J Radiat Oncol Biol Phys.* 2012;83(4):e487-493. doi:10.1016/j.ijrobp.2011.10.021
57. Goda JS, Dutta D, Krishna U, et al. Hippocampal radiotherapy dose constraints for predicting long-term neurocognitive outcomes: mature data from a prospective trial in young patients with brain tumors. *Neuro Oncol.* 2020;22(11):1677-1685. doi:10.1093/neuonc/noaa076
58. Acharya S, Wu S, Ashford JM, et al. Association between hippocampal dose and memory in survivors of childhood or adolescent low-grade glioma: a 10-year neurocognitive longitudinal study. *Neuro Oncol.* 2019;21(9):1175-1183. doi:10.1093/neuonc/noz068
59. Brown PD, Chung C, Liu DD, et al. A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. *Neuro Oncol.* 2021;23(8):1337-1347. doi:10.1093/neuonc/noab040
60. Mohan R, Liu AY, Brown PD, et al. Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. *Neuro Oncol.* 2021;23(2):284-294. doi:10.1093/neuonc/noaa182
61. Le Rhun E, Oppong FB, Vanlancker M, et al. Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. *Neuro Oncol.* 2022;24(9):1533-1545. doi:10.1093/neuonc/noac070
62. Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. *Neuro-oncology.* 2013;15(10):1429-1437. doi:10.1093/neuonc/not114

63. Gehring K, Sitskoorn MM, Gundy CM, et al. Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. *J Clin Oncol*. 2009;27(22):3712-3722. doi:10.1200/JCO.2008.20.5765
64. Aizer AA, Du R, Wen PY, Arvold ND. Radiotherapy and death from cerebrovascular disease in patients with primary brain tumors. *J Neurooncol*. 2015;124(2):291-297. doi:10.1007/s11060-015-1839-5
65. Dominguez M, Malani R. Stroke-Like Migraine Attacks After Radiation Therapy (SMART) Syndrome: A Comprehensive Review. *Curr Pain Headache Rep*. 2021;25(5):33. doi:10.1007/s11916-021-00946-3
66. Minniti G, Traish D, Ashley S, Gonsalves A, Brada M. Risk of Second Brain Tumor after Conservative Surgery and Radiotherapy for Pituitary Adenoma: Update after an Additional 10 Years. *The Journal of Clinical Endocrinology & Metabolism*. 2005;90(2):800-804. doi:10.1210/jc.2004-1152
67. Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. *JAMA*. 2017;318(23):2306-2316. doi:10.1001/jama.2017.18718
68. Lacouture ME, Anadkat MJ, Ballo MT, et al. Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma. *Front Oncol*. 2020;10:1045. doi:10.3389/fonc.2020.01045
69. Oberheim-Bush NA, Shi W, McDermott MW, Grote A, Stindl J, Lustgarten L. The safety profile of Tumor Treating Fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts. *J Neurooncol*. 2022;158(3):453-461. doi:10.1007/s11060-022-04033-4
70. McClelland S, Henrikson CA, Ciporen JN, Jaboin JJ, Mitin T. Tumor Treating Fields Utilization in a Glioblastoma Patient with a Preexisting Cardiac Pacemaker: The First Reported Case. *World Neurosurg*. 2018;119:58-60. doi:10.1016/j.wneu.2018.07.162
71. Ashby L, Hasselle M, Chowdhary S, Fathallah-Shaykh H, Zhu JJ. ATCT-04RETROSPECTIVE ANALYSIS OF TUMOR TREATING FIELDS (TTFIELDS) IN ADULTS WITH GLIOBLASTOMA: SAFETY PROFILE OF THE OPTUNE<sup>TM</sup> MEDICAL DEVICE IN PATIENTS WITH IMPLANTED NON-PROGRAMMABLE SHUNTS, PROGRAMMABLE SHUNTS, AND PACEMAKERS/DEFIBRILLATORS. *Neuro Oncol*. 2015;17(suppl 5):v1.4-v1. doi:10.1093/neuonc/nov206.04
72. Shoji T, Kanamori M, Inoue J, et al. Hepatitis B virus reactivation during temozolomide administration for malignant glioma. *Int J Clin Oncol*. 2021;26(2):305-315. doi:10.1007/s10147-020-01814-7
73. Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, van Putten WL. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. *Neurology*. 1994;44(4):675-680. doi:10.1212/wnl.44.4.675

74. Pitter KL, Tamagno I, Alikhanyan K, et al. Corticosteroids compromise survival in glioblastoma. *Brain*. 2016;139(Pt 5):1458-1471. doi:10.1093/brain/aww046
75. Roth P, Happold C, Weller M. Corticosteroid use in neuro-oncology: an update. *Neuro-Oncology Practice*. 2015;2(1):6-12. doi:10.1093/nop/npu029
76. Iorgulescu JB, Gokhale PC, Speranza MC, et al. Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. *Clin Cancer Res*. 2021;27(1):276-287. doi:10.1158/1078-0432.CCR-20-2291
77. Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. *Nat Rev Clin Oncol*. 2021;18(3):170-186. doi:10.1038/s41571-020-00447-z
78. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med*. 2005;352(10):987-996. doi:10.1056/NEJMoa043330
79. Damato AR, Luo J, Katumba RGN, et al. Temozolomide chronotherapy in patients with glioblastoma: a retrospective single-institute study. *Neurooncol Adv*. 2021;3(1):vdab041. doi:10.1093/noajnl/vdab041
80. Climans SA, Grunfeld E, Mason WP, Chan KKW. Effectiveness and safety of pneumocystis pneumonia prophylaxis for patients receiving temozolomide chemoradiotherapy. *Neuro-Oncology*. Published online March 21, 2022:noac072. doi:10.1093/neuonc/noac072
81. Climans SA, Mason WP, Grunfeld E, Chan K. Clinical features of glioma patients who develop pneumocystis pneumonia with temozolomide chemoradiotherapy. *J Neurooncol*. 2022;159(3):665-674. doi:10.1007/s11060-022-04109-1
82. Larkin PJ, Cherny NI, La Carpia D, et al. Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2018;29(Suppl 4):iv111-iv125. doi:10.1093/annonc/mdy148
83. Weller M, Gorlia T, Cairncross JG, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. *Neurology*. 2011;77(12):1156-1164. doi:10.1212/WNL.0b013e31822f02e1
84. Spiro T, Liu L, Gerson S. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance. *Forum (Genova)*. 2000;10(3):274-285.
85. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. *Br J Cancer*. 2000;83(5):588-593. doi:10.1054/bjoc.2000.1316
86. Kraft SL, Baker NM, Carpenter J, Bostwick JR. Procarbazine and antidepressants: a retrospective review of the risk of serotonin toxicity. *Psychooncology*. 2014;23(1):108-113. doi:10.1002/pon.3378
87. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine,



lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. *J Clin Oncol*. 2006;24(18):2715-2722. doi:10.1200/JCO.2005.04.6078

88. Weller M, Le Rhun E. How did lomustine become standard of care in recurrent glioblastoma? *Cancer Treat Rev*. 2020;87:102029. doi:10.1016/j.ctrv.2020.102029

89. Weiss RB, Issell BF. The nitrosoureas: carmustine (BCNU) and lomustine (CCNU). *Cancer Treat Rev*. 1982;9(4):313-330. doi:10.1016/s0305-7372(82)80043-1

90. Wick W, Gorlia T, Bendszus M, et al. Lomustine and Bevacizumab in Progressive Glioblastoma. *N Engl J Med*. 2017;377(20):1954-1963. doi:10.1056/NEJMoa1707358

91. Seliger C, Nürnberg C, Wick W, Wick A. Lung toxicity of lomustine in the treatment of progressive gliomas. *Neurooncol Adv*. 2022;4(1):vdac068. doi:10.1093/noajnl/vdac068

92. van den Bent MJ, Brandes AA, Taphoorn MJB, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. *J Clin Oncol*. 2013;31(3):344-350. doi:10.1200/JCO.2012.43.2229

93. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. *J Clin Oncol*. 2013;31(3):337-343. doi:10.1200/JCO.2012.43.2674

94. Dennison JB, Kulanthaivel P, Barbusch RJ, Renbarger JL, Ehlhardt WJ, Hall SD. Selective metabolism of vincristine in vitro by CYP3A5. *Drug Metab Dispos*. 2006;34(8):1317-1327. doi:10.1124/dmd.106.009902

95. Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms? *Neurosci Lett*. 2015;596:90-107. doi:10.1016/j.neulet.2014.10.014

96. Jordan B, Margulies A, Cardoso F, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. *Ann Oncol*. 2020;31(10):1306-1319. doi:10.1016/j.annonc.2020.07.003

97. Zawacki WJ, Walker TG, DeVasher E, et al. Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy. *J Vasc Interv Radiol*. 2009;20(5):624-627; quiz 571. doi:10.1016/j.jvir.2009.01.022

98. Kaley T, Touat M, Subbiah V, et al. BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study. *J Clin Oncol*. Published online October 23, 2018;JCO2018789990. doi:10.1200/JCO.2018.78.9990

99. Wen PY, Stein A, van den Bent M, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. *Lancet Oncol*. 2022;23(1):53-64. doi:10.1016/S1470-2045(21)00578-7

100. Anforth R, Fernandez-Peñas P, Long GV. Cutaneous toxicities of RAF inhibitors. *Lancet Oncol.* 2013;14(1):e11-18. doi:10.1016/S1470-2045(12)70413-8
101. Thawer A, Miller WH, Gregorio N, et al. Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements. *Curr Oncol.* 2021;28(5):3537-3553. doi:10.3390/curroncol28050304
102. Atkinson V, Robert C, Grob JJ, et al. Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. *Eur J Cancer.* 2022;163:79-87. doi:10.1016/j.ejca.2021.12.015
103. Torre M, Vasudevaraja V, Serrano J, et al. Molecular and clinicopathologic features of gliomas harboring NTRK fusions. *Acta Neuropathol Commun.* 2020;8(1):107. doi:10.1186/s40478-020-00980-z
104. Ferguson SD, Zhou S, Huse JT, et al. Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas. *J Neuropathol Exp Neurol.* 2018;77(6):437-442. doi:10.1093/jnen/nly022
105. Woo HY, Na K, Yoo J, et al. Glioblastomas harboring gene fusions detected by next-generation sequencing. *Brain Tumor Pathol.* 2020;37(4):136-144. doi:10.1007/s10014-020-00377-9
106. Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. *Lancet Oncol.* 2020;21(4):531-540. doi:10.1016/S1470-2045(19)30856-3
107. Martineau C, Turcotte MK, Otis N, et al. Management of adverse events related to first-generation tyrosine receptor kinase inhibitors in adults: a narrative review. *Support Care Cancer.* 2022;30(12):10471-10482. doi:10.1007/s00520-022-07401-y
108. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol.* 2020;21(2):271-282. doi:10.1016/S1470-2045(19)30691-6
109. Lambertini M, Peccatori FA, Demeestere I, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†. *Ann Oncol.* 2020;31(12):1664-1678. doi:10.1016/j.annonc.2020.09.006
110. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. *J Clin Oncol.* 2000;18(16):3038-3051. doi:10.1200/JCO.2000.18.16.3038
111. Griffiths EA, Roy V, Alwan L, et al. NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022. *J Natl Compr Canc Netw.* 2022;20(5):436-442. doi:10.6004/jnccn.2022.0026
112. Lyman GH, Kuderer NM, Crawford J, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. *Cancer.* 2011;117(9):1917-1927.

doi:10.1002/cncr.25691

113. Neuwelt AJ, Nguyen TM, Fu R, et al. Incidence of *Pneumocystis jirovecii* pneumonia after temozolomide for CNS malignancies without prophylaxis. *CNS Oncol.* 2014;3(4):267-273. doi:10.2217/cns.14.24
114. Takeuchi K, Yakushijin Y. *Pneumocystis jirovecii* Pneumonia Prophylaxis for Cancer Patients during Chemotherapy. *Pathogens.* 2021;10(2):237. doi:10.3390/pathogens10020237
115. Neumann S, Krause SW, Maschmeyer G, et al. Primary prophylaxis of bacterial infections and *Pneumocystis jirovecii* pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Ann Hematol.* 2013;92(4):433-442. doi:10.1007/s00277-013-1698-0
116. Le Rhun E, Oppong FB, Vanlancker M, et al. Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. *Neuro Oncol.* Published online March 21, 2022:noac070. doi:10.1093/neuonc/noac070
117. Le Rhun E, Guckenberger M, Smits M, et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. *Ann Oncol.* 2021;32(11):1332-1347. doi:10.1016/j.annonc.2021.07.016
118. Schiffer CA, Bohlke K, Delaney M, et al. Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol.* 2018;36(3):283-299. doi:10.1200/JCO.2017.76.1734
119. Le Rhun E, Devos P, Houillier C, et al. Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial. *Neurology.* 2019;93(19):e1799-e1806. doi:10.1212/WNL.00000000000008440
120. Carson JL, Guyatt G, Heddle NM, et al. Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage. *JAMA.* 2016;316(19):2025-2035. doi:10.1001/jama.2016.9185
121. Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. *Ann Oncol.* 2018;29(Suppl 4):iv96-iv110. doi:10.1093/annonc/mdx758
122. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. *Br J Cancer.* 2010;102(2):301-315. doi:10.1038/sj.bjc.6605498
123. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. *J Natl Cancer Inst.* 2006;98(10):708-714. doi:10.1093/jnci/djj189
124. Gergal Gopalkrishna Rao SR, Bugazia S, Dhandapani TPM, et al. Efficacy and Cardiovascular Adverse Effects of Erythropoiesis Stimulating Agents in the Treatment of Cancer-Related Anemia: A Systematic Review of Randomized Controlled Trials. *Cureus.*

2021;13(9):e17835. doi:10.7759/cureus.17835

125. Dixit S, Baker L, Walmsley V, Hingorani M. Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review. *Anticancer Drugs*. 2012;23(10):1099-1106. doi:10.1097/CAD.0b013e328356f5b0

126. Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. *Anticancer Drugs*. 2014;25(2):225-234. doi:10.1097/CAD.0000000000000032

127. Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncol*. 2018;4(4):495-504. doi:10.1001/jamaoncol.2017.5082

128. Doz F, van Tilburg CM, Geoerger B, et al. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. *Neuro Oncol*. 2022;24(6):997-1007. doi:10.1093/neuonc/noab274

129. O'Driscoll BR, Kalra S, Gattamaneni HR, Woodcock AA. Late carmustine lung fibrosis. Age at treatment may influence severity and survival. *Chest*. 1995;107(5):1355-1357. doi:10.1378/chest.107.5.1355

130. Dhakal S, Weiner D, Schwartz C, Constine LS. Pulmonary Effects of Antineoplastic Therapy. *Survivors of Childhood and Adolescent Cancer*. Published online April 13, 2015:201-227. doi:10.1007/978-3-319-16435-9\_11

131. Heinzerling L, Eigentler TK, Fluck M, et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. *ESMO Open*. 2019;4(3):e000491. doi:10.1136/esmoopen-2019-000491

132. Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. *Ther Adv Med Oncol*. 2015;7(2):122-136. doi:10.1177/1758834014566428

133. Dixit S, Baker L, Walmsley V, Hingorani M. Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review. *Anticancer Drugs*. 2012;23(10):1099-1106. doi:10.1097/CAD.0b013e328356f5b0

134. Duan ZY, Liu JQ, Yin P, Li JJ, Cai GY, Chen XM. Impact of aging on the risk of platinum-related renal toxicity: A systematic review and meta-analysis. *Cancer Treat Rev*. 2018;69:243-253. doi:10.1016/j.ctrv.2018.07.002

135. Narita Y. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors. *Jpn J Clin Oncol*. 2013;43(6):587-595. doi:10.1093/jjco/hyt051

136. Taal W, Oosterkamp HM, Walenkamp AME, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. *Lancet Oncol*. 2014;15(9):943-953. doi:10.1016/S1470-2045(14)70314-6

137. Reardon DA, Brandes AA, Omuro A, et al. Effect of Nivolumab vs Bevacizumab in

Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. *JAMA Oncol*. Published online May 21, 2020. doi:10.1001/jamaoncol.2020.1024

138. O'Reilly M, Mellotte G, Ryan B, O'Connor A. Gastrointestinal side effects of cancer treatments. *Ther Adv Chronic Dis*. 2020;11:2040622320970354. doi:10.1177/2040622320970354

139. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*. 2017;35(28):3240-3261. doi:10.1200/JCO.2017.74.4789

140. Habets EJJ, Taphoorn MJB, Klein M, Vissers T, Dirven L. The level of reporting of neurocognitive outcomes in randomised controlled trials of brain tumour patients: A systematic review. *Eur J Cancer*. 2018;100:104-125. doi:10.1016/j.ejca.2018.05.014

141. Seet RCS, Rabinstein AA. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. *QJM*. 2012;105(1):69-75. doi:10.1093/qjmed/hcr139

142. Van Pelt Q, Stragier E, Roelandt P, Van Cutsem E. Posterior reversible encephalopathy syndrome secondary to oxaliplatin-based chemotherapy and regorafenib in metastatic colorectal cancer : case reports and literature review. *Acta Gastroenterol Belg*. 2020;83(1):47-50.

143. Lee JH, Choi YS. The role of gonadotropin-releasing hormone agonists in female fertility preservation. *Clin Exp Reprod Med*. 2021;48(1):11-26. doi:10.5653/term.2020.04049

144. Mulder RL, Font-Gonzalez A, Hudson MM, et al. Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Lancet Oncol*. 2021;22(2):e45-e56. doi:10.1016/S1470-2045(20)30594-5

145. Oktay K, Harvey BE, Partridge AH, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. *J Clin Oncol*. 2018;36(19):1994-2001. doi:10.1200/JCO.2018.78.1914

146. Massarotti C, Scaruffi P, Lambertini M, Remorgida V, Del Mastro L, Anserini P. State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature. *Cancer Treat Rev*. 2017;57:50-57. doi:10.1016/j.ctrv.2017.04.009

147. ESHRE Guideline Group on Female Fertility Preservation, Anderson RA, Amant F, et al. ESHRE guideline: female fertility preservation. *Hum Reprod Open*. 2020;2020(4):hoaa052. doi:10.1093/hropen/hoaa052

148. Wo JY, Viswanathan AN. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. *Int J Radiat Oncol Biol Phys*. 2009;73(5):1304-1312. doi:10.1016/j.ijrobp.2008.12.016



Table 1. Mode of administration and laboratory values required to allow treatment initiation (expert opinion).

	Dosing	Mode of administration	Preconditions for drug administration						Prophylaxis	Laboratory controls
			Neutrophils	Lymphocyte	Platelets	Hemoglobin	Liver enzymes	Others		
Temozolomide	<p>75 mg/m<sup>2</sup> during radiotherapy 7 days a week;</p> <p>150-200 mg/m<sup>2</sup> (days 1-5 out of 28 days) as a single agent</p> <p>Minimal dose during maintenance: 100 mg/m<sup>2</sup></p>	<p>Oral, i.v. application no longer available;</p> <p>Capsules should be swallowed whole with approximately 250 mL (one glass) of water while fasting, in the morning, i.e., at least 1 h before a meal or 2 h after a meal.</p> <p>Concomitant with RT, capsules should be taken approximately 1 h before administration of RT</p>	≥1.5 x 10 <sup>9</sup> /L	-	≥100 x 10 <sup>9</sup> /L	-	Normal liver function	Non-hematological toxicity CTCAE grade ≤ 1, except for alopecia, nausea and vomiting	<p><b>Anti-emetic prophylaxis</b>  <b>Concomitant:</b> 5-HT<sub>3</sub>-antagonists usually only required for the initial 2-3 doses of temozolomide. Then simple antiemetic prophylactic treatment with metoclopramide or domperidone is sufficient for most patients, some patients may not require any antiemetic.  <b>Maintenance:</b> Strongly recommended prophylaxis: 5-HT<sub>3</sub>-antagonist, low dose, e.g., ondansetron 4 mg or granisetron 1 mg p.o. 1 h prior to temozolomide administration.</p> <p><b>Pneumocystis jirovecii prophylaxis</b>  <b>Concomitant:</b> Per label required for all patients regardless of lymphocyte count during RT and beyond until any lymphopenia has recovered to CTCAE grade ≤ 1, but debatable for patients without corticosteroids and without lymphopenia  <b>Maintenance:</b> all patients if lymphocytes ≤ 0.8 x 10<sup>9</sup>/L (CTCAE grade ≥ 1) or CD4 count ≤ 200/μL, particularly patients receiving steroids should be observed closely for the development of pneumocystis jirovecii pneumonia  <b>Proposed prophylaxis:</b> Pentamidine inhalations by nebulizer once a month or Trimethoprim-sulfamethoxazole (Bactrim forte®) 1 tablet/3 x per week</p>	<p>During concomitant radiochemotherapy: weekly complete blood count and liver enzymes;</p> <p>During maintenance: complete blood count (days 21 and 28) and, liver enzymes at days 21</p>
Procarbazine	100 – 150 mg	Oral	≥1.5 x	-	≥100 x	-	-	non-	5-HT <sub>3</sub> -antagonist, low dose, e.g.,	

	daily, in the PCV protocol 60 mg/m <sup>2</sup> on days 8 through 21		10 <sup>9</sup> /L		10 <sup>9</sup> /L			hematological toxicity grade ≤ 1, except for alopecia, nausea and vomiting	ondansetron 4 mg or granisetron 1-2 mg p.o. 1 h prior to administration	
Lomustine	130 mg/m <sup>2</sup> single agent, 110 mg/m <sup>2</sup> , in the PCV protocol or in combination with bevacizumab commonly capped at 200 mg, x 6-8 weeks	Oral	≥1.5 x 10 <sup>9</sup> /L	-	≥100 x 10 <sup>9</sup> /L	-	-	non-hematological toxicity grade ≤ 1, except for alopecia, nausea and vomiting  pulmonary examination and nerve conduction studies prior to first cycle not routinely, but only with appropriate history	Recommended prophylaxis: 5-HT <sub>3</sub> -antagonist or metoclopramide p.o. 1 h prior to lomustine administration	at days 28 and 35 complete blood counts, at day 42 complete blood count and blood chemistry
Vincristine	2 mg, days 8 and 29 in the PCV protocol	i.v.	≥1.5 x 10 <sup>9</sup> /L	-	≥100 x 10 <sup>9</sup> /L	-	-	Discontinuation for any clinical signs of peripheral neuropathy		Complete blood count, vincristine alone is only weakly myelosuppressive, but commonly given with together other myelosuppressive agents
PCV		Oral and i.v.	≥1.5 x 10 <sup>9</sup> /L	-	≥100 x 10 <sup>9</sup> /L	-	-	See Lomustine, Procarbazine and vincristine  pulmonary examination and nerve conduction studies prior to first cycle not routinely, but	Recommended prophylaxis: 5-HT <sub>3</sub> -antagonist or metoclopramide p.o. 1 h prior to lomustine administration, 5-HT <sub>3</sub> -antagonist on day 1 and 2 p.o. 1 h prior procarbazine and metoclopramide as needed during procarbazine administration	At day 8 and day 29 complete blood counts, after week 6 complete blood count and blood chemistry

								only with appropriate history		
Bevacizumab	10 mg/kg x 14 days or 15 mg/kg x 3 weeks i.v.	i.v.	$\geq 1.5 \times 10^9/L$	-	$\geq 100 \times 10^9/L$	-	-	Liver function: CTCAE grade 1 allowed  Microproteinuria allowed	-	Complete blood count and liver enzymes every 14 days and additional urine status 48 hours before next infusion cycles.  Weekly or even shorter controls might be necessary depending on laboratory values.  Blood pressure prior / during and after infusion  Careful assessment for any clinical signs of deep vein thrombosis  Educate patients to report immediately any signs of shortness of breath (pulmonary embolism or myocardial infarction) or abdominal pain
Vemurafenib	960 mg twice daily	Oral  Avoid concomitant administration with strong CYP3A4 inhibitors or inducers	$\geq 1.5 \times 10^9/L$	-	$\geq 75 \times 10^9/L$	-	-	ECG (QT time)  Dermatological examination prior to drug initiation	Avoid sun exposure, use of sunscreen, not to be used during RT	Every 4 weeks blood counts and blood chemistry including electrolytes, first 3 months monthly ECG (QT time), thereafter every 3 months Dermatological examination every



										3 months
Dabrafenib/ trametinib	Dabrafenib 2 mg daily, trametinib 150 mg twice daily	Oral Take dabrafenib and trametinib with water at least one hour before or two hours after a meal  Avoid concurrent administration of strong inhibitors of CYP3A4 or CYP2C8	$\geq 1.5 \times 10^9/L$	-	$\geq 75 \times 10^9/L$			cardiac function: ECG, left ventricular ejection fraction  Dermatological examination prior to drug initiation	Avoid sun exposure, use of sunscreen, not to be used during RT	Every 4 weeks blood counts and blood chemistry including electrolytes  Monthly control of blood pressure  Every three months left ventricular ejection fraction  Dermatological examination every 3 months
Larotrectinib and entrectinib	Larotrectinib: 100 mg twice daily; minimal dose: 50 mg twice daily  Symptoms of overdose are not established. In the event of overdose, physicians should follow general supportive measures and treat symptomatically.  Entrectinib: 600 mg once daily; minimal dose: 200 mg once daily.	<u>Larotrectinib</u> Oral (capsule or oral solution); capsules or oral solution should be swallowed whole with approximately 250 mL (one glass) of water with or without food but should not be taken with grapefruit or grapefruit juice.  <u>Entrectinib</u> Capsules or oral solution should be swallowed whole with approximately 250 mL (one glass) of water with or without food but should not be taken with grapefruit or grapefruit juice.	CTCAE grade 1 and 2 allowed	$\geq 1 \times 10^9$	$\geq 100 \times 10^9/L$	CTCAE grade 1 and 2 allowed	Normal liver function	-	No specific prophylaxis  Potential interaction with other medications (such as anti-HIV drugs, sartans, statins, anti- diabetics, warfarin) to be considered  Women using systemically acting hormonal contraceptives should be advised to add a barrier method.	Liver function: before the first dose and monthly for the first 3 months of treatment, then periodically during treatment, with more frequent testing in patients who develop transaminase elevations.  Patients with grade 2 ALT and/or AST increases should be followed with serial laboratory evaluations every one to two weeks

Abbreviations: ALT: alanine transaminase, AST: aspartate aminotransferase, CTCAE: Common Terminology Criteria for Adverse Events, HIV: human immunodeficiency virus i.v.: intravenous, kg: kilogramm, mg: milligramm, mL: milliliters, p.o.: per os, RT: radiotherapy

Table 2. Frequency of CTCAE grade 3/4 hematological toxicity (%) by drug in primary brain tumor trials.\*

	Neutropenia	Lymphopenia	Thrombocytopenia	Anemia	References
Temozolomide	7	7	12	1	Stupp et al. 2005 <sup>76</sup>
Procarbazine	3	Not specified	4	2	Yung et al. 2000 <sup>82</sup>
Lomustine	20	0	25	2.4	Wick et al. 2010 <sup>146</sup>
Vincristine	-	-	-	-	No single agent data, probably low risk
PCV	32	Not specified	21	7	Van den Bent et al. 2006 <sup>84</sup>
Bevacizumab	0 0	0 2.3	0 0	0 0	Kreisl et al. 2011 <sup>147</sup> Odia et al. 2014 <sup>148</sup>
Vemurafenib	-	-	-	2	Larkin et al. 2014 <sup>149</sup>
Dabrafenib/ tramatenib	10	-	-	-	Wen et al. 2022 <sup>96</sup>
Larotrectinib (n=33, including only 7 adults)	3	Not reported	Not reported	0	Doz et al. 2022 <sup>125</sup>
Entrectinib	-	-	-	-	No data

\*See dedicated chapters for management of these toxicities and reexposure to therapy.

Table 3. Frequency of CTCAE grade 3/4 non-hematological toxicity by drug in primary brain tumor trials.

	Toxicity (%)	%	References	Management and consequences for tumor-specific treatment
Temozolomide	Fatigue	13	Stupp et al. 2005 <sup>76</sup>	
	Skin	3		Pause until resolution, reexpose
	Nausea, vomiting	2		Enforce antiemetic treatment
	Infection	7		Antibiotics
	Hepatotoxicity	rare		Stop treatment and assess relatedness with hematologist
Procarbazine	Nausea and vomiting	3	Yung et al. 2000 <sup>82</sup>	Dose reduction or stop
	Fatigue	2		Dose reduction
	Rash	25		Stop treatment
Lomustine	Nausea	23	Wick et al. 2010 <sup>146</sup>	Enforce antiemetic treatment
	Infection	4		Dose reduction
	Hepatotoxicity	not reported		Dose reduction or discontinue
Vincristine	Polyneuropathy			Stop in case of signs of polyneuropathy
PCV	Nausea (mostly lomustine-related)		Van den Bent et al. 2006 <sup>84</sup> , Wick et al. 2009 <sup>150</sup>	Prevent with 5-HT3 antagonists
	Rash (grades 2/3)	1-10		Stop procarbazine, regardless of grade
	Polyneuropathy (grades 2/3)	2-7		Stop vincristine once signs appear
	Hepatotoxicity (grades 2/3)	10		Dose reduction of procarbazine first, then lomustine
	Asthenia, lack of appetite, weight loss	5		Mild cases: metoclopramide, if severe: dose reduction or stop procarbazine
Bevacizumab	Hypertension grade 3 or 4	4.2	Gilbert et al. 2014 <sup>151</sup>	Treat with antihypertensive medication and continue. Dose reduction recommended depending on severity of antihypertensive medication. Consider extension of

		11.3	Chinot et al. 2014 44	treatment intervals up to 4-6 weeks between infusions.
Proteinuria		5.4	Chinot et al. 2014 44	Treatment interruption up to normalization. Consider dose reduction or extension of treatment intervals, e.g. 4-6 weeks between infusions
Fatigue		5-13.1	Gilbert et al. 2014 151	Consider specific physical activity
Venous thromboembolic events		4.6 7.6	Gilbert et al. 2014 151  Chinot et al. 2014 44	Anticoagulation and continuation of therapy without dose reduction
Arterial thromboembolic events		5	Chinot et al. 2014 44	Evaluation of stroke etiology, reevaluation of treatment continuation
Hemorrhage, not further specified		1.6 2	Gilbert et al. 2014 151  Chinot et al. 2014 44	Treatment discontinuation
Cerebral hemorrhage grade 4				
Bleeding outside the CNS		1.3	Chinot et al. 2014 44	Treatment interruption. evaluation of bleeding severity and available clinical strategies. Evaluate dose adaptation or treatment discontinuation
Wound dehiscence		1.3-1.6 3.3	Gilbert et al. 2014 151  Chinot et al. 2014 44	Treatment interruption. Continue without dose reduction after complete wound healing
Nausea and vomiting		1-4.2	Gilbert et al. 2014 151	5-HT3 antagonists, no treatment interruption or dose reduction
Visceral perforation		1.2 1.1	Gilbert et al. 2014 151  Chinot et al. 2014	Treatment discontinuation

			44	
Vemurafenib	Skin Arthralgia Liver function Fatigue	5-15 3 5 3	Larkin et al. 2014 <sup>149</sup>	Dose interruption and dose reduction
Larotrectinib (n=33, including 7 adults)	Dysphagia Pneumonia Vomiting Headache Pyrexia Urinary tract infection	6 6 3 3 3 3	Doz et al. 2022 <sup>125</sup>	Dose interruption and dose reduction

\*alternative causes of toxicity should always be explored